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Background: The use of bone marrow concentrate (BMC) for treatment of musculoskeletal 
disorders has become increasingly popular over the last several years, as technology has improved 
along with the need for better solutions for these pathologies. The use of cellular tissue raises a 
number of issues regarding the US Food and Drug Administration’s (FDA) regulation in classifying 
these treatments as a drug versus just autologous tissue transplantation. In the case of BMC in 
musculoskeletal and spine care, this determination will likely hinge on whether BMC is homologous 
to the musculoskeletal system and spine. 
Objectives: The aim of this review is to describe the current regulatory guidelines set in place by 
the FDA, specifically the terminology around “minimal manipulation” and “homologous use” within 
Regulation 21 CFR Part 1271, and specifically how this applies to the use of BMC in interventional 
musculoskeletal medicine. 
Methods: The methodology utilized here is similar to the methodology utilized in preparation of 
multiple guidelines employing the experience of a panel of experts from various medical specialties 
and subspecialties from differing regions of the world. The collaborators who developed these 
position statements have submitted their appropriate disclosures of conflicts of interest. Trustworthy 
standards were employed in the creation of these position statements. The literature pertaining to 
BMC, its effectiveness, adverse consequences, FDA regulations, criteria for meeting the standards of 
minimal manipulation, and homologous use were comprehensively reviewed using a best evidence 
synthesis of the available and relevant literature.
Results/Summary of Evidence: In conjunction with evidence-based medicine principles, the 
following position statements were developed: 
Statement 1: Based on a review of the literature in discussing the preparation of BMC using 
accepted methodologies, there is strong evidence of minimal manipulation in its preparation, and 
moderate evidence for homologous utility for various musculoskeletal and spinal conditions qualifies 
for the same surgical exemption. 
Position Statement
Bone Marrow Concentrate (BMC) Therapy in 
Musculoskeletal Disorders: Evidence-Based 
Policy Position Statement of American Society of 
Interventional Pain Physicians (ASIPP)
Address Correspondence: 
Christopher J. Centeno, MD
Centeno-Schultz Clinic






For affiliations, disclaimer and 









Laxmaiah Manchikanti, MD, Christopher J. Centeno, MD, Sairam Atluri, MD, Sheri L. Albers, DO, 
Shane Shapiro, MD, Gerard A. Malanga, MD, Alaa Abd-Elsayed, MD, Mairin Jerome, MD,
Joshua A. Hirsch, MD, Alan D. Kaye, MD, PhD, Steve M. Aydin, DO, Douglas Beall, MD, 
Don Buford, MD, Joanne Borg-Stein, MD, Ricardo Buenaventura, MD, Joseph A. Cabaret, MD, 
Aaron K. Calodney, MD, Kenneth D. Candido, MD, Cameron Cartier, MD, Richard Latchaw, MD, 
Sudhir Diwan, MD, Ehren Dodson, PhD, Zachary Fausel, MD, Michael Fredericson, MD, 
Christopher G. Gharibo, MD, Mayank Gupta, MD, Adam M. Kaye, PharmD, FASCP, FCPhA, 
Nebojsa Nick Knezevic, MD, PhD, Radomir Kosanovic, MD, Matthew Lucas, DO, 
Maanasa V. Manchikanti, R. Amadeus Mason, MD, Kenneth Mautner, MD, Samuel Murala, MD, 
Annu Navani, MD, Vidyasagar Pampati, MSc, Sarah Pastoriza, DO, Ramarao Pasupuleti, MD, 
Cyril Philip, MD, Mahendra Sanapati, MD, Theodore Sand, PhD, Rinoo Shah, MD, Amol Soin, MD, 
Ian Stemper, MS, Bradley W. Wargo, DO, and Philippe Hernigou, MD
www.painphysicianjournal.com
Pain Physician 2020; 23:E85-E131 • ISSN 2150-1149
Statement 2: Assessment of clinical effectiveness based on extensive literature shows emerging evidence for multiple 
musculoskeletal and spinal conditions.
•  The evidence is highest for knee osteoarthritis with level II evidence based on relevant systematic reviews, ran-
domized controlled trials and nonrandomized studies. There is level III evidence for knee cartilage conditions. 
•  Based on the relevant systematic reviews, randomized trials, and nonrandomized studies, the evidence for disc 
injections is level III.
•  Based on the available literature without appropriate systematic reviews or randomized controlled trials, the 
evidence for all other conditions is level IV or limited for BMC injections. 
Statement 3: Based on an extensive review of the literature, there is strong evidence for the safety of BMC when performed by 
trained physicians with the appropriate precautions under image guidance utilizing a sterile technique.
Statement 4: Musculoskeletal disorders and spinal disorders with related disability for economic and human toll, despite 
advancements with a wide array of treatment modalities.
Statement 5: The 21st Century Cures Act was enacted in December 2016 with provisions to accelerate the development and 
translation of promising new therapies into clinical evaluation and use. 
Statement 6: Development of cell-based therapies is rapidly proliferating in a number of disease areas, including musculoskeletal 
disorders and spine. With mixed results, these therapies are greatly outpacing the evidence. The reckless publicity with unsubstantiated 
claims of beneficial outcomes having putative potential, and has led the FDA Federal Trade Commission (FTC) to issue multiple 
warnings. Thus the US FDA is considering the appropriateness of using various therapies, including BMC, for homologous use.
Statement 7: Since the 1980’s and the description of mesenchymal stem cells by Caplan et al, (now called medicinal signaling 
cells), the use of  BMC in musculoskeletal and spinal disorders has been increasing in the management of pain and promoting 
tissue healing. 
Statement 8: The Public Health Service Act (PHSA) of the FDA requires minimal manipulation under same surgical procedure 
exemption. Homologous use of BMC in musculoskeletal and spinal disorders is provided by preclinical and clinical evidence. 
Statement 9: If the FDA does not accept BMC as homologous, then it will require an Investigational New Drug (IND) classification 
with FDA (351) cellular drug approval for use. 
Statement 10: This literature review and these position statements establish compliance with the FDA’s intent and corroborates 
its present description of BMC as homologous with same surgical exemption, and exempt from IND, for use of BMC for treatment 
of musculoskeletal tissues, such as cartilage, bones, ligaments, muscles, tendons, and spinal discs.
Conclusions: Based on the review of all available and pertinent literature, multiple position statements have been developed 
showing that BMC in musculoskeletal disorders meets the criteria of minimal manipulation and homologous use.
Key words: Cell-based therapies, bone marrow concentrate, mesenchymal stem cells, medicinal signaling cells, Food and Drug 
Administration, human cells, tissues, and cellular tissue-based products, Public Health Service Act (PHSA), minimal manipulation, 
homologous use, same surgical procedure exemption 
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young and elderly alike (12). The disability and cost of 
health care continue to increase despite the number of 
available treatment modalities and significant increases 
in health care expenditures (3-49). Consequently, a shift 
in health care strategies has been advocated involving 
novel pharmacologic and biological therapies that can 
effectively treat these disorders. 
Musculoskeletal disorders represent a major cause of morbidity and result in enormous costs for health and social care systems (1-
11). Chronic and inflammatory diseases of joints and the 
spine, including osteoarthritis, and low back pain caused 
by intervertebral disc degeneration with involvement 
of the 3-joint complex, are major causes of disability in 
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Development of cell-based therapies is being rap-
idly incorporated into treatment plans for a number of 
disease processes, including musculoskeletal disorders 
and spine. The results are mixed. The use of cell-based 
therapy is greatly outpacing the evidence (12,49-71). 
The public awareness that biologics have regenera-
tive potential has been acknowledged by their highly 
publicized use in professional athletes, and because of 
the national debate on embryonic stem cells (49,72). 
Consequently, the result of this irresponsible publicity 
with unsubstantiated claims of miraculous outcomes 
(57) has led the Federal Trade Commission (FTC) to take 
action against stem cell therapy clinics found to be in 
violation of the truth in advertising law (58). In addi-
tion, misrepresentation of uncharacterized, minimally 
manipulated, allogenic cell preparation as “stem cells,” 
or the use of more than minimally manipulated cell 
preparations, have led to a widespread clinical use of 
unproven biologic therapies (49,73,74). The US Food 
and Drug Administration (FDA) has had no recourse 
but to investigate multiple stem cell clinics and publish 
new guidance (59-74). Physicians using bone marrow-
derived medicinal signaling cells or mesenchymal stem 
cells (BM-MSC) therapy must elucidate, justify, and rec-
ommend that the FDA consider bone marrow concen-
trate (BMC) as “homologous use.” The sheer volume of 
unsubstantiated claims and lack of high-level research 
has led to a health Canada policy position paper on the 
use of autologous cell therapy products (75). In addi-
tion, concerns over misinformation and inappropriate 
application of stem cell therapy have led to recent calls 
to action from professional organizations including the 
National Academy of Sciences (NAS), the International 
Society for Cellular Therapy (ISCT), the American As-
sociation for the Advancement of Science (AAAS), the 
American Academy Orthopedic Surgeons (AAOS), and 
American Society of Interventional Pain Physicians 
(ASIPP) (3,49,50,76-78). Each of these groups recognize 
the potential value of cell therapies and the risk that 
the current environment may erode the public trust. 
Responsible investments are needed to bring legitimate 
cellular and biological therapies to patients (49). 
Regenerative medicine continues to develop based 
on the scientific principles of evidence-based medicine 
with its effectiveness shown in multiple musculoskeletal 
disorders and in managing spinal pain (3,49,50,78-112). 
In contrast to traditional medical therapies, stem cell-
based therapies integrate tissue-engineering technolo-
gies and biomaterial science fundamental to the science 
of regenerative medicine. Thus, tissue engineering 
approaches for cartilage and intervertebral disc repair 
will benefit from advances in MSCs based repair strate-
gies (106). 
The 21st Century Cures Act was enacted in Decem-
ber 2016, with provisions to accelerate the develop-
ment and translation of promising new therapies into 
clinical evaluation and use (52,113). This bipartisan and 
bicameral legislation increased funding for medical 
research, and for combatting the opioid epidemic, in-
cluding measures to streamline approval of new thera-
pies for clinical trials (49,52). The 21st Century Cures 
Act also provided a new expedited biologics product 
development program called Regenerative Medicine 
Advanced Therapy (RMAT) (63). The key elements of 
RMAT include accelerated FDA approval for regenera-
tive medicine therapy that is intended to treat a condi-
tion and shows a potential to address unmet clinical 
needs for some diseases or conditions, such as chronic 
musculoskeletal and spine conditions.
In regenerative medicine the present focus of 
cell therapy has been on 2 types of stem cells, namely 
bone marrow-derived stem cells and adipose-derived 
stem cells. However, with the FDA regulations on stem 
cell therapy, adipose-derived cell therapies have been 
considered as a drug. Thus BMC is currently the only 
viable strategy left in the United States covered under 
the 21 CFR 1271.15 (b) same surgical exemption despite 
many emerging autologous cell therapy products. Un-
fortunately, some countries, including Canada, have 
regulated all types of stem cells, essentially restricting 
cell therapy in their countries (75).
Bone marrow is the organ responsible for the 
generation of blood and immune cells, with mesen-
chymal cells supporting hematopoiesis (107,108,114). 
Bone marrow transplants begin in the 1960s and be-
ginning in the 1980s, BMC began to be used in mus-
culoskeletal pathologies. Based on the therapeutic 
properties of the cells and growth factors contained 
in the bone marrow, its use has been tested in several 
types of disease entities and injuries with positive out-
comes, including musculoskeletal disorders and spinal 
disorders (108,114-118). Historically, Till and McCull-
och (117) in 1963 demonstrated that bone marrow 
transplantation (BMT) was able to reconstitute the 
hematopoietic system of mice that had their system 
completely depleted by irradiation. In 1966, Frieden-
stein et al (115) showed that bone marrow contained 
a distinct type of cell capable of forming bone tis-
sue when cultured in diffusion chambers and then 
implanted in mice. These cells were later described 
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as mesenchymal cells (116). Since then, in the 1980s, 
Arnold Caplan and colleagues published their work 
on the isolation of MSCs from BMC and the ability of 
these cells to differentiate into bone and cartilage in 
specific in vitro conditions (107,119-122). Caplan (120) 
also renamed mesenchymal stem cells as medicinal 
signaling cells with the acronym remaining the same–
MSCs. Since Caplan, there has been rapid expansion 
of the basic and clinical literature investigating the 
potential therapeutic application of stem cell therapy 
and regenerative medicines (3,49,50,79-108). In vitro 
studies showed that (BM-MSCs can be purified, culture 
expanded, and induced to differentiate into mesoder-
mal tissue types (57,123-125). Investigations into po-
tential clinical applications for musculoskeletal injury 
and disease (including spinal disorders), range from 
a variety of soft issue biologic treatment modalities, 
including direct soft tissue and osseous injections, as 
well as intravascular therapy to intraarticular therapy, 
and intradiscal therapy, all of which have increased 
exponentially (50). Despite the development of a 
clinical and therapeutic basis for use of BM-MSCs and 
other forms of stem cell therapy, clinical applications 
have far outpaced the basic and transitional science 
required to confirm their potential effectiveness and 
safety (3,46,50-71,107,126-134).
The Public Health Service Act (PHSA) defines the 
laws surrounding the control of the spread of com-
municable diseases in organ or tissue transplants. 
The FDA has since created regulations found in 21 
CRR 1271 based on the PHSA, which control the use 
of human cells, tissues, and cellular and tissue-based 
products (HCT/Ps), including both autologous and 
allogenic bone marrow-derived tissue preparations 
(52,61,62,135). Two broad categories of tissue prepa-
rations intended to be injected or infused into human 
recipients are described in 21 CFR 1271 applying to 
HCT/Ps that are minimally manipulated and intended 
for homologous use (135) or those that are more than 
minimally manipulated or intended not to be used in 
a homologous way. The FDA described that the pro-
cessing procedure for minimally manipulated cells or 
tissues must not “alter the original relevant character-
istics relevant to the tissues’ utility for reconstructive, 
repair, and replacement,” and must not “alter relevant 
biological characteristics of cells or tissue.” Further, 
the FDA defines homologous use as, “the repair, re-
construction, replacement, or supplementation of the 
recipient’s cells or tissues with an HCT/P that performs 
the same basic function or functions in the recipient as 
in the donor” (135). In addition to these 2 important 
aspects of the regulation, 21 CFR 1271 also requires 
that the cells are not combined with any other tissue 
or product except for “water, crystalloids, or a steriliz-
ing, preserving, or storage agent.” Thus cell and tissue 
preparations that meet the criteria described in 1271 
can be administered to patients without obtaining 
premarket clearance or an investigational new drug 
(IND) classification from the FDA.
In addition, if the HCT/Ps have passed a minimal 
manipulation test as described earlier, then they are 
eligible to be exempt under 21 CFR 1271.15(b). This 
same surgical procedure exemption contemplates that 
the cells are extracted and reintroduced into the same 
patient (autologous) during the same surgical proce-
dure (135).
Based on the FDA regulation and present concepts, 
autologous BMC meets the definitions of minimal ma-
nipulation without controversy. In addition, it meets 
the definition of the 21 CFR 1271.15(b) same surgical 
procedure exemption as well. However, the second as-
pect of the definition, which is homologous use when 
used to treat musculoskeletal applications, has still yet 
to be decided. This issue has evolved into not only a 
subject of discussion, but also of concern based on the 
Canadian position on autologous cell therapy products 
(75). A Health Canada Policy position paper with the 
regulatory frameworks under the Food and Drug Act 
provided oversight of safety, efficacy, and quality, while 
enabling patient access to potentially promising new 
therapies in 2019, declared that autologous cell therapy 
products meeting the definition of “drug” in persons 
who prepare or manufacture and administer or distrib-
ute must comply with Sections 8 and 11 of the Food 
and Drug Act (75,136,137). This Health Canada policy 
change now includes BMC in the “drug” category. 
However, Health Canada continues to work to identify 
and overcome challenges specific to meeting regula-
tory requirements for the manufacturing and sale of 
autologous cell therapy products.
Other international regulatory authorities, such 
as the European Medicine Agency, have laws similar to 
Canada’s that allow them to regulate the distribution 
of cell therapy products in their respective jurisdictions. 
However, the European Union has enacted regulations 
specifically for cell therapy products, whereas US FDA 
and Health Canada applied existing drug regulatory 
frameworks. In addition, some regulatory authorities 
have special exemptions for cell therapy products, in-
cluding those that are prepared at the bedside during 
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the “same surgical procedure” or “hospital exemp-
tions” where all of the tissue processing with adminis-
tration occurs within the same establishment.
In reviewing US FDA guidance documents, the 
way in which the FDA ultimately addresses this is-
sue will depend on classification of bone marrow as 
“homologous” or “nonhomologous.” Fulfillment of 
this criteria for autologous BMC that is used as part of 
same surgical procedure exemptionis required for this 
procedure to be regulated by the state medical boards 
and not the FDA. If BMC does not meet all of these cri-
teria it will fall outside of the same surgical procedure 
exemption and require an IND classification with FDA 
approval for use. Therefore to be FDA compliant and 
exempt from an IND, the use of BMC for treatment 
of musculoskeletal tissues, such as cartilage, bone, 
ligaments, muscle, tendons, and spinal discs, must be 
considered homologous.
This position paper provides a comprehensive, fo-
cused review of bone marrow MSC therapy. This policy 
position paper describes the current regulatory guide-
lines set in place by the FDA, specifically the terminol-
ogy around “homologous use” with specific application 
to BMC. 
ASIPP has been at the forefront of guideline de-
velopment for the use of interventional techniques, 
opioids, and biologics in the management of low back 
pain, antithrombotics in interventional techniques, and 
the use of sedation (3,4,138-140). The present position 
statement has been developed to describe the role of 
BM-MSCs therapy in musculoskeletal disorders, with 
a comprehensive review of the literature of BM-MSC 
therapy. This position statement includes an overview 
of the current literature applicable to BMC and MSC ap-
plications in the musculoskeletal system, including the 
spine. This position statement specifically incorporates 
the various aspects of FDA guidance and provides a ba-
sis for asserting that BMC meets the criteria for minimal 




The National Uniform Claims Committee (NUCC) 
defines interventional pain management as the disci-
pline of medicine devoted to the diagnosis and treat-
ment of pain-related disorders, principally with the 
application of interventional techniques in managing 
subacute, chronic, persistent, and intractable pain, 
independently or in conjunction with other modalities 
of treatment (141). In addition, the Medicare Payment 
Advisory Commission (MedPAC) defines interventional 
pain management techniques as “minimally invasive 
procedures including percutaneous precision needle 
placement of drugs in targeted areas or ablation of 
targeted nerves; surgical techniques such as laser and 
endoscopic discectomy; and the placement of intrathe-
cal infusion pumps and spinal cord stimulators for the 
diagnosis and management of chronic, persistent, or 
intractable pain” (142).
Chronic musculoskeletal and spinal pain are com-
plex and multifactorial disease processes. The high 
prevalence of chronic musculoskeletal and spinal pain, 
the numerous treatment modalities applied in the man-
agement of the problem, and the growing social and 
economic costs continue to influence medical decision-
making. Interventional pain physicians are familiar with 
various image-guided interventional techniques for the 
management of spinal pain and musculoskeletal pain. 
The technical skills and training required for the various 
delivery methods of BMC fall well within interventional 
pain managements purview. 
Objectives 
This position paper provides a comprehensive, fo-
cused review of bone marrow MSC therapy. This policy 
position paper describes the current regulatory guide-
lines set in place by the FDA, specifically the terminol-
ogy around “homologous use” with specific application 
to BMC. 
Adherence to Trustworthy Standards 
In preparation of this position statement for BMC, 
the standards from the Institute of Medicine (IOM) and 
the National Guideline Clearinghouse Extent Adher-
ence to Trustworthy Standards (NEATS) were followed 
(143-145). The NEATS instrument was developed and 
tested as a tool to be used with strict adherence by the 
trained staff at the Agency for Healthcare Research and 
Quality (AHRQ) in providing an assessment focused on 
NEATS. 
Disclosure of Funding Source for Position 
Statement 
The evidence-based policy position statement on 
BMC therapy in musculoskeletal and spinal disorders 
were commissioned, prepared, edited, and endorsed 
by ASIPP without seeking or obtaining any external 
funding.
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Disclosure and Management of Financial Conflicts 
of Interest 
Potential conflicts of interest for all panel members 
within the last 5 years were evaluated prior to the final-
izing of these guidelines. Conflicts of interests extend-
ed beyond financial relationships, including personal 
experiences, practice patterns, academic interests, and 
promotions. Participants with previously established 
conflicts are considered those with opinions not being 
in line with the previously developed ASIPP guidelines 
or the overall philosophical approach of ASIPP. The 
panel members with potential conflicts were recused 
from discussion or preparation of the guidelines in 
which they had conflicts of interest, and these members 
agreed not to discuss any aspect of a given guideline 
with the related industry before data publication.
Composition of Position Development Group
A panel of experts in BMC from various medical 
fields, convened by ASIPP, reviewed the evidence and 
formulated recommendations for BMC therapy as it ap-
plies to musculoskeletal and spinal disorders. The panel 
constituted a broad representation of academic and 
non-academic clinical practitioners with an interest and 
expertise in the application of BMC in musculoskeletal 
and spinal disorders.
Evidence Review 
This position statement was developed with con-
sensus among the panel members after review of the 
published literature concerning the use and safety of 
BMC therapy in musculoskeletal and spinal disorders 
with chronic noncancer pain. 
The recommendations for this position statement 
have been developed using the principles of best 
evidence synthesis developed by Cochrane Review, and 
have incorporated  multiple guidelines modified by 
ASIPP, as shown in Table 1 (146).
Grading or Rating the Quality or Strength of 
Evidence
An evidence-based position statement has both 
similarities and differences when compared with prac-
tice guidelines. For the development of this position 
statement, the evidence is based on literature review 
and consensus. The traditional instruments for the 
grading of evidence based on randomized controlled 
trials, observational studies, and other clinical reports, 
with a major focus on systematic reviews and meta-
analysis may not be utilized, to the same extent as in 
the preparation of guidelines (3,4,138,140). However, 
the grading of evidence based on ASIPP guidelines, 
founded on the quality of evidence and the strength of 
recommendations as proposed by AHRQ (144,145), as 
shown in Table 2, were utilized.
Assessment and Recommendations of Benefits 
and Harms 
This position statement clearly describes 
the potential beneficial evidence summary 
recommendations. 
Evidence Summary of Recommendations 
This position statement summarizes the relevant 
supporting evidence.
Specificity of the Statement 
This position statement is specific and unambigu-
ous, providing guidance on BMC therapy in musculo-
skeletal and spinal disorders.
Table 1. Qualitative modified approach to grading of  evidence.
Level I Strong Evidence obtained from multiple relevant high-quality randomized controlled trials for effectiveness.
Level II Moderate Evidence obtained from at least one relevant high-quality randomized controlled trial or multiple relevant moderate or low-quality randomized controlled trials.
Level III Fair Evidence obtained from at least one relevant high-quality nonrandomized trial or observational study with multiple moderate- or low-quality observational studies. 
Level IV Limited Evidence obtained from multiple moderate- or low-quality relevant observational studies. 
Level V Consensus based Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to assess preventive measures, adverse consequences, effectiveness of other measures.
Adapted from Manchikanti L, Falco FJE, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. Pain Phy-
sician 2014; 17:E319-E325 (146).
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External Review 
This position statement has been subjected to ex-
ternal peer review as per the policies of the publishing 
journal, Pain Physician.
Updating the Position Statement 
BMC therapy in musculoskeletal disorders will be 
updated within 5 years or less, based on significant 
changes in the scientific evidence, public policy, or ad-
verse events occurring on or before March 2025.
IMpact of Musculoskeletal dIsorders
Health Care and Disability 
Health care expenditures have been escalating 
over the years. Recent estimates of the US health care 
spending reached $3.66 trillion in 2018 (147). In addi-
tion, expenditures will continue to grow each year with 
estimates showing that national health expenditures 
will grow at an average annual growth rate of 5.5% 
from 2018 to 2027 (148). Simply put, the 2018 cost 
of $3.65 trillion in spending represents $11,212 per 
person, but keeping all variables stable, that cost per 
person in 2027 will rise to $12,197.04. US spending 
on personal and public health care from 1996 to 2013 
(1), showed an estimated spending of $87.6 billion in 
managing low back and neck pain, and $95.5 billion 
in managing musculoskeletal disorders, with a total 
spending on musculoskeletal disorders and spinal pain 
of approximately $183 billion.
The impact of chronic pain is enormous (1,2,4-
9,12,138,147-155). The annual US expenditures alone 
(including direct medical costs and lost wages) may 
be higher than those for cancer, heart disease, and 
diabetes combined (1,2,5). Despite high expenditures 
and numerous treatment option, disability continues to 
escalate. Figure 1 shows expenditures related to mus-
culoskeletal conditions, including back and neck pain, 
as determined in 2016 based on US spending on health 
care (1). 
Musculoskeletal conditions are the leading contrib-
utors to disability in the United States and worldwide. 
In addition to musculoskeletal pain contributing to 
disability, it has also been associated with a number of 
conditions in older people, such as low physical activity, 
poor mobility, frailty, depression, cognitive impairment, 
and poor sleep quality (155).
A study of the state of the US health between 1990 
and 2010, describing the burden of diseases, injuries, 
and risk factors (6), showed that with increasing life 
expectancy, morbidity, and chronic disability accounted 
for nearly half of the US health burden, despite substan-
tial progress and improvement in health. Among the 30 
leading diseases and injuries contributing to years lived 
with disability in the United States between 1990 and 
2010, low back pain, other musculoskeletal disorders, 
and neck pain ranked numbers 1, 3, and 4, respectively 
(6). More recent analysis of the state of US health from 
1990 to 2016 (7) showed similar results with low back 
pain, other musculoskeletal disorders, and neck pain 
ranking numbers 1, 4, and 6, respectively. Similar to low 
back pain, other musculoskeletal disorders (specifically 
osteoarthritis) caused substantial pain and disability 
impacting the quality of life. Hip and knee osteoarthri-
tis has been ranked at the 11th highest contributor to 
global disability, and 38th highest in years lived with 
disability (156).
Chronic persistent spinal pain lasting longer 
than 1 year is reported in 25% to 60% of patients 
(3,8,138,157). Similarly, the prevalence of knee and hip 
Table 2. Guide for strength of  recommendations.
Rating for Strength of  Recommendation
Strong
There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true 
net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns 
about study quality; and/or d) the extent the panelists’ agreement. Other compelling considerations (discussed in the 
guideline’s literature review and analyses) may also warrant a strong recommendation.
Moderate
There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for 
a true net effect (e.g., benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/
or few concerns about study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations 
(discussed in the guideline’s literature review and analyses) may also warrant a moderate recommendation. 
Weak
There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) 
limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; 
c) concerns about study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the 
guideline’s literature review and analyses) may also warrant a weak recommendation. 
Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (144).
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osteoarthritis is over 25% in individuals over the age 
of 45 (158). Although the literature shows that over 
27 million adults in the United States age 25 years and 
older have a clinical diagnosis of osteoarthritis of any 
joint, 5.6 million cases of these present with lower 
extremity osteoarthritis (159-163). It is also estimated 
that 13 million adults age 60 years and older in the 
United States have radiographic osteoarthritis, with ap-
proximately 4 million of those individuals classified as 
having symptomatic knee osteoarthritis (162). Further, 
individuals sustaining a knee injury are 4.2 times more 
likely to develop osteoarthritis than those without a 
history of knee injury (164). In addition to osteoarthritis 
of hip and knee, shoulder osteoarthritis is ranked as the 
third most common cause of osteoarthritis. A multitude 
of other osteoarthritis conditions occur commonly after 
trauma (162). 
Of the estimated spending of $264.3 billion as 
annual expenditures for musculoskeletal disorders, 
including spinal disorders, as shown by Dieleman et al 
(1,2), $134.6 billion was spent in managing low back 
and neck pain, an increase from $87.6 billion in 2013, a 
44.4% increase from $183.5 billion from 2013 to 2016 
for musculoskeletal disorders and spinal disorders. A 
multitude of other assessments have also shown sig-
nificant health care spending and its impact for muscu-
loskeletal disorders. An IOM study (5) showed the cost 
of chronic pain to range from $560 to $635 billion per 
year, which includes spinal pain, chronic pain, and other 
painful conditions (Table 3) (5,150,165). The literature 
has been explicit in showing unsustainable increases 
in all types of therapies starting with over-the-counter 
drug therapy, alternative modalities to prescription 
drugs, conservative management, minimally invasive 
procedures, and surgical interventions (3,4,10-49). 
Thus, the impact of musculoskeletal disorders on 
health care is enormous with substantial human toll 
leading to a multitude of issues, the most important 
being disability with reduced quality of life.
Opioid Epidemic
Opioid use has become a major issue in the United 
Fig. 1. Estimated health care spending by aggregated age group, type of  payer, and aggregated health category in 2016.
Reported in 2016 US dollars. Each of the 3 columns sums to the estimated $2.7 trillion of 2016 spending disaggregated in this study. The width 
of each line reflects the relative share of the estimated $2.7 trillion attributed to that age group, type of payer, or aggregated health category. 
aIncludes maternal, neonatal, and nutritional disorders.
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States, with its escalating use, treatment costs, and 
preventative measures used in effort to control the ex-
plosion of the opioid epidemic (4,13,16,23,25,166-181). 
The US drug overdosage data of drug-related deaths 
from 2017 shows escalating statistics with over 70,000 
drug overdoses, of which 47,600 were related to opioid 
overdoses, as shown in Fig. 2 (177). It has been shown 
that the majority of the increases are related to syn-
thetic opioids, as well as heroin. The recent data shows 
a 14.5% drop in prescription drug opioid deaths to less 
than 12,000. However, heroin deaths continue to in-
crease, and in 2017 there were over 15,000 deaths due 
to heroin, as shown in Fig. 3. Fentanyl deaths are the 
category largely responsible for the escalating opioid 
epidemic (178).
Sixty-three percent of deaths involve various other 
drugs in addition to prescription opioids with 34% 
cocaine, 33% benzodiazepines, and 12% methamphet-
amines (179). Even though deaths due to prescription 
opioids are declining, the overall opioid deaths continue 
to increase. Further, the age-old comparison of increas-
ing prescriptions correlating with increasing deaths has 
been nullified now that prescriptions are declining (Fig. 
4). In fact, opioid prescription data in the United States 
shows a significant decline from 251.8 million prescrip-
tions in 2013 to 168.8 million prescriptions in 2018, as 
shown in Fig. 5 (181).
Even though there is overwhelming evidence 
that the epidemic of opioid use involves not only the 
use of prescription opioids, but fentanyl and heroin, 
policy experts appear to have focused on prescription 
opioids as the main target in the United States (16). 
Manchikanti et al (16) described various issues related 
to the opioid epidemic and pointed out the tragic fail-
ure of current systems to control opioid misuse. It was 
this misuse that propagated the epidemic, starting 
with the pain movement together with a confluence 
of interest and failure of oversight from the opioid in-
dustry, which was largely responsible for the epidemic. 
Multiple issues related to the confluence of interest in-
cluded promotion of opioids based on inadequate evi-
dence with advocacy from Portenoy and Foley (182). 
Subsequently, the Fifth Vital Sign was established in 
1995, which became a universal phenomenon (16). 
Further, fuel was added by guidelines implemented 
Table 3. The prevalence and cost of  chronic pain. 
♦The annual cost of chronic pain is $560 to $635 billion a year 
 • Direct cost due to pain is $261 – $300 billion
♦Prevalence estimates
 • 10% moderate pain
 • 11% severe pain  Total 21%
 • 33% joint pain
 • 25% arthritis






Source: Gaskin DJ, Richard P. The economic costs of pain in the Unit-
ed States. J Pain 2012; 13:715-724 (149).
 
Fig. 2. National drug overdose 
deaths—number among all 
ages, 1999 to 2017.
Source: Centers for Disease 
Control and Prevention, National 
Center for Health Statistics. 
Multiple Cause of Death 1999-
2017 on CDC WONDER Online 
Database, released December, 
2018 (177).
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Fig. 4. Opioid prescriptions at 10-year low and overdose deaths at 10-year high.
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by the medical boards. These guidelines were written 
theoretically for appropriate opioid usage, but were 
essentially being developed by the opioid industry. 
There were also failures in oversight of not only opioid 
manufacturing, distribution, diversion, and import, 
but also in medical necessity and appropriate monitor-
ing of opioid prescriptions (16).
The significant movement to control the opioid 
epidemic in the United States was initiated with pre-
scription drug monitoring programs, state regulations, 
curbing opioid productions, and increasing the focus on 
education. Overall federal spending increasing by 128% 
from 2017 to 2018 with the major increases in federal 
spending due to treatment and recovery programs with 
costs ranging from approximately $599 million to $2.1 
billion (183-195). Total opioid spending increased from 
$3.3 billion in 2017 to $7.4 billion in 2018 in the United 
States (183). The numerous regulations and enhanced 
prescription drug monitoring programs have also con-
tributed to the decreases in opioid prescriptions from 
a high of 255 million in 2012 to 191 million in 2017, a 
decrease of 25%.
Overall the decline in the number of prescriptions 
with reduced dosages, faces a multitude of criticisms 
against the Centers for Disease Control and Prevention 
(CDC) guidelines and other measures (193-198). Conse-
quently, US Department of Health & Human Services, 
as well as the CDC, have clarified and are encouraging 
providing opioids for patients with appropriate medi-
cal necessity, even though they continue to focus on 
reduced utilization (197,198).
BMc
Bone marrow is a semi-solid tissue found within 
spongy or cancellous portions of bones. The cellular 
components of bone marrow include osteoblasts, os-
teoclasts, macrophages, endothelial progenitor cells 
(EPCs), hematopoietic stem cells (HSCs), and MSCs 
(108,199). BMC, also known as bone marrow aspirate 
concentrate (BMAC), is created by centrifuging bone 
marrow aspirate. This process results in 3 layers with the 
plasma in the supernatant, the buffy coat in the middle, 
and the red blood cell layer in the infranatant (108). 
To create BMC, the buffy coat is isolated. Contained 
in this layer is a number of cells, including MSCs, HSCs, 
myelopoietic and erythropoietic cells, mature leuko-
cytes, platelets, and megakaryocytes (108). Among the 
cellular components, MSCs are largely credited with the 
therapeutic potential of BMC to treat musculoskeletal 
pathology due to their ability to self-replicate and dif-
ferentiate into other cell types such as osteoblasts and 
chondrocytes (200).
The use of bone marrow in medicine can be traced 
back to the 1940s and 1950s when the first discoveries 
of irradiating and protecting mice with a BMT were 
performed (201). Studies followed showing leukemic 
mice could be treated by infusion of normal mouse 
bone marrow (201-203). Early human studies infusing 
Fig. 5. Total opioid 
prescriptions in the 
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allogeneic marrow were ineffective at establishing a 
graft other than in identical twins (201-203). The first 
successful graft treatment in a human patient with 
leukemia was published in 1965 (204,205). By the late 
1960s, increasing knowledge of human histocompat-
ibility antigen systems made successful BMT possible 
(201). By the 1970s, BMT became more commonly used 
in refractory cases of leukemia (205). In the late 1980s, 
Caplan and colleagues published their work on the 
isolation of the MSCs from the bone marrow and the 
ability of MSCs to differentiate into bone and cartilage 
in vitro (107,119-122).
There has been significant discussion in reference 
to the effectiveness of BMC and in the nomenclature, 
as well as the inconsistencies (206). The ISCT in 2016 
defined specific criteria that must be met for cells to 
be considered MSCs. The criteria included that the cells 
must be plastic-adherent in standard culture conditions, 
must display specific surface antigens, and must show 
in vitro differentiation into osteoblasts, adipocytes, and 
chondroblasts (207). As the understanding continues to 
evolve, MSCs have been defined as mesenchymal stem 
cell, mesodermal stem cell, and mesenchymal stromal 
cell, often simultaneously by different groups that con-
tinue to disagree on the most accurate name for the cell 
type (120). In addition, based on the ability to undergo 
in vitro osteogenesis and costochondral genesis (206-
208), MSCs were initially thought to maintain their mul-
tipotency after injection into an injured joint. Thus the 
term “mesenchymal stem cell” was used to describe the 
hypothesized ability to differentiate and regenerate in-
jured cartilage or soft tissue (107). However, subsequent 
evidence has demonstrated that MSCs are rather derived 
from pericytes or perivascular cells surrounding capillary 
endothelium (120-122,209). Further, studies also have 
suggested that injected MSCs do not undergo differen-
tiation in vivo and the primary functionality is not that of 
a stem cell (210,211). Despite the hypothesis that MSCs 
are no longer thought to exhibit stem-like properties in 
vivo, they have been shown to induce endogenous stem 
cell activity and secrete bioactive factors that promote 
tissue healing (122,212-217). Consequently, the perivas-
cular source and immunomodulary effects of the BMC 
make both “stem cell” and “stromal cell” inaccurate 
descriptions of MSCs. This has led to a modification of 
the meaning of MSC being changed from “mesenchymal 
stem cell” to “medicinal signaling cell” to emphasize 
their role as trophic mediators by Caplan (120).
Charbord (206) in a review provided the historical 
emergence of the concept of bone marrow MSCs, sum-
marizing the data on hematopoietic inductive micro-
environment (218), hematopoiesis supportive stromal 
cells (219), osteogenic cells (220), trilineal osteoblastic, 
chondrocytic, and adipocytic precursors (124,220), to 
finally introduce the specific bone marrow MSCs with 
differentiation potential, and stromal and immuno-
modulatory capacities. Charbord (206) described 2 
points in detail. The first point envisioned the stem cell 
attributes as having multipotentiality, self-renewal, tis-
sue regeneration, population heterogeneity, plasticity, 
and lineage priming, compared with the attributes of 
paradigmatic HSCs. In the second point, believing the 
possible existence of bone marrow cells with even larg-
er differentiation potential, eventually pluripotential 
cells were discussed. This review led to the conclusion 
that bone marrow MSCs can constitute a specific adult 
tissue stem cell population. The multiple characteristics 
of this stem cell type accounts for the versatility of the 
mechanisms of injured tissue repair.
In a consensus statement, Chu et al (49) describe 
the characteristics of stem cells and minimally manipu-
lated autologous cell preparations with BMC, as shown 
in Table 4 (221). 
Since the discovery of MSCs, BMC has been used 
extensively to treat musculoskeletal diseases since the 
1980s (222). The first case series on the use of BMC to 
treat nonunion fracture and avascular necrosis was 
published by Hernigou et al (223) in the mid-2000s. In 
the last decade, many physicians have started utilizing 
BMC to address common musculoskeletal conditions, 
such as osteoarthritis and tendon injuries. The body of 
literature to support this use is growing and at pres-
ent includes multiple randomized controlled trials 
(49,80,81,87-112,224-248). 
us fda regulatory context
The FDA uses the term “human cells, tissues or 
tissue-based products” (or “HCT/Ps”) when describing 
human cells or tissues that are “intended for implanta-
tion, transplantation, infusion or transfer into a human 
recipient.” The FDA’s regulation of HCT/Ps involves a 
tiered risk structure and a multipart test (135).
The “tiered, risk-based approach” to the regula-
tion of HCT/Ps was first announced by the FDA in 1997, 
and was finalized in regulations found at 21 CFR Part 
1271 in 2005. The 21 CFR Part 1271.10 includes an 
important criteria through which all HCT/Ps must be 
vetted to determine whether any specific HCT/P will 
be subject to the FDA’s IND and Biologics License Ap-
plication requirements, or will merely qualify for the 
www.painphysicianjournal.com  E97
BMC Therapy in Musculoskeletal Disorders: Position Statement of ASIPP
Table 4. Characteristics of  MSCs and minimally manipulated cell preparations of  BMC. 
Cell Type Definition
MSCs Three minimum characteristics: 
1. Capable of division and self-renewal for long periods of time
2. Unspecialized 
3. Can give rise to specialized cell types
BMC, minimally manipulated autologous cell 
preparations
Cleared for homologous use
Processing must not alter the relevant biological characteristics of cells or tissues
Mixed cell populations, with variable composition
Stem or progenitor cells may be present at lower prevalence
Biological attributes and function highly variable
Adapted from: Chu CR, Rodeo S, Bhutani N, et al. Optimizing clinical use of biologics in orthopaedic surgery: Consensus recommendations from 
the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg 2019; 27:e50-e63 (49).
Part 1271 regulations themselves (135). In the present 
context (physician use in offices or operating rooms), 
these regulations create a binary regulatory pathway in 
which one category is regulated only by the Part 1271 
regulations themselves, whereas the other is regulated 
as a drug requiring the full gamut of the FDA drug ap-
proval process.  
Autologous HCT/Ps that are either “more than 
minimally manipulated” or used for a “nonhomolo-
gous” purpose are deemed by the FDA to present more 
risk and cannot be used in the United States without 
the FDA’s permission in the form of an approved IND or 
biologic license application. Alternatively, autologous 
HCT/Ps that are “minimally manipulated” and used for 
homologous purposes may either be regulated as a tis-
sue product, subject to FDA’s registration, listing, in Part 
1271 requirements, or as surgical procedures, which 
would fall into FDA’s “same surgical procedure” exemp-
tion found at 21 CFR 1271.15 and regulated primarily 
at the state level. Finally, bone marrow is exempt from 
regulation as an HCT/P if it is minimally manipulated 
and used for a homologous purpose; 21 CFR 1271.3(d) 
(135). Hence throughout this analysis, the HCT/Ps that 
are minimally manipulated and also used for a homolo-
gous purpose fall within critical distinctions that govern 
how the HCT/P is regulated. 
Given the minimal processing involved in the cre-
ation of BMC, it fits under the FDA’s minimal manipu-
lation definition. Indeed, using a parallel example in-
volving a blood product, the FDA wrote in its guidance 
that when a “manufacturer performs cell selection…to 
obtain a higher concentration of hematopoietic stem/
progenitor cells (HPCs) for transplantation…[t]he HCT/P 
would generally be considered minimally manipulated 
because the concentrated peripheral blood stem/pro-
genitor cells are not altered with regard to their rel-
evant biological characteristic” (249). 
However, the second part of the regulatory classifi-
cation, homologous use, is now open to interpretation. 
This paper will address this last remaining question, 
that is what constitutes the “homologous use” of au-
tologous bone marrow? Homologous use is defined 
as “the repair, reconstruction, replacement, or supple-
mentation of a recipient’s cells or tissues with an HCT/P 
that performs the same basic function or functions in 
the recipient as in the donor” 21 CFR Part 1271.3(c). 
However, with respect to bone marrow, to date the 
FDA has only provided the following guidance: 
First, in a subsequently withdrawn Guidance Docu-
ment published in 2016, the FDA wrote as follows: “The 
basic functions of hematopoietic stem/progenitor cells 
(HPCs) include to form and to replenish the hemato-
poietic system. Sources of HPCs include cord blood, 
peripheral blood, and bone marrow.” Thus as of 2016, 
if a procedure involved the use of HPCs to address a 
disorder affecting the hematopoietic system, the proce-
dure would have been considered to be a homologous 
use of the HPCs (250). 
Second, in its finalized Guidance dated November 
2017, the FDA wrote as follows: “Sources of hemato-
poietic stem/progenitor cells (HPCs) include cord blood, 
peripheral blood, and bone marrow. The basic func-
tions of HPCs include forming and replenishing the 
lymphohematopoietic system” (249). Thus as of today, 
if a procedure involves the use of HPCs to address a dis-
order affecting the lymphohematopoietic system, the 
procedure will be considered the homologous use of 
the HPCs. 
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Hence what the existing medical literature states 
about how the body uses bone marrow to maintain or 
heal musculoskeletal and spinal disorders will have a 
profound effect on the regulation of BMC in musculo-
skeletal medicine. In other words, if BMC is homologous 
to common musculoskeletal tissues and disc, then it is 
left unregulated by the FDA, but if nonhomologous, 
then it can be classified as a drug, and is subject to the 
FDA’s drug approval requirement (135).
IMpact of Bone Marrow cells on healIng
As shown in the literature, the historical emergence 
of the concept of bone marrow mesenchymal cells is 
complex with a number of clinical applications ranging 
from musculoskeletal to neurologic indications, but 
more specifically musculoskeletal disorders as described 
herewith.
Bone 
Bone has the ability to self-repair largely because 
the cells responsible for initiation and completion of 
the repair reside within the bone marrow. Many of 
these bone marrow cells are capable of osteogenesis 
and vasculogenesis (251). This osteogenic potential has 
prompted many physicians through the decades to use 
bone grafts or bone marrow to help heal delayed-union 
and nonunion fractures (252). The components in bone 
marrow that help bone naturally heal are those present 
in BMC.
Bone marrow is a multifunctional mixture of anu-
cleate red blood cells and platelets, as well as nucleated 
cells that include multipotent stem cells and progeni-
tor cells (253). The nucleated cells within this mixture 
have hematopoietic, angiogenic, and osteogenic po-
tential (254). The 3 primary multipotent cell types that 
populate bone marrow are HSCs, MSCs, and EPCs. Bone 
marrow’s essential functions include hematopoiesis, 
osteogenesis, and vasculogenesis (255). 
When a fracture occurs, the liquid portion of the 
bone marrow flows into the space created. The cellular 
content of this liquid is believed to drive the fracture 
repair (251). The osteogenic potential of bone marrow 
was first discovered in BM-MSCs in the 1960s (256,257), 
with later work illuminating MSCs’ ability to differen-
tiate into osteoblasts and osteocytes depending on 
local environmental cues (125,258). It has been shown 
in vitro and in vivo that a single HSC can also have 
hematopoietic or osteogenic potential depending on 
environmental factors and the surrounding conditions 
(259).  
Vasculogenesis is another essential function of 
bone marrow cells (260). Bone healing has been shown 
to occur via mobilization of EPCs from bone marrow, 
which encourage vasculogenesis in the setting of struc-
tural damage and ischemia (254,260-262). Bone marrow 
cells require transportation via this newly established 
vasculature to initiate the healing cascade, induce 
callus formation, and instigate bone remodeling and 
healing (253). Evidence suggests special populations 
of EPCs in specific bone marrow niches are available 
for rapid release in response to ischemic conditions, as 
well as matrix metalloproteinases (MMPs). This environ-
ment induces tubulization and new vessel formation to 
restore adequate oxygen delivery and allow for bony 
remodeling (262-264). 
Surgeons have long used the ability of bone to heal 
fractures by utilizing the natural elements found in 
structural bone and bone marrow. For example, autolo-
gous and allogeneic bone grafts have been commonly 
used for more than a century to heal nonunion fracture 
(252). In the 1990s, Hernigou et al (222,264) again pub-
lished on the use of autologous BMC to heal nonunion 
fracture in addition to its application in the treatment 
of avascular necrosis.  
BMC contains multipotent cells capable of os-
teogenesis, as well as growth factors, cytokines, and 
chemokines active in osteopoiesis (265-267). It has been 
shown that an intraosseous injection of BMC can help 
heal nonunion fracture by replenishing the native and 
healthy cellular composition of the normal bone (126). 
Hence injecting BMC into the bone is performed, in 
part, to reestablish osteogenic potential with newly en-
grafted cells that can serve to replace and/or enhance 
native cell functionality (199).  
Cartilage  
Cartilage is an avascular tissue made up of chon-
drocytes and extracellular matrix (ECM) that consists 
of water, collagen, and proteoglycans (251). It derives 
its nutrition and ability for self-repair largely by its 
communication with the underlying bone marrow 
through the subchondral plate. This natural relation-
ship between bone and cartilage has been utilized by 
surgeons to help heal cartilage lesions using bone mar-
row stimulation techniques since the late 1980s to early 
1990s (268,269).
Articular cartilage is produced during bone devel-
opment when chondrocytes are replaced by osteoblasts 
in the long bone during the endochondral ossification 
process (270). It is important in the overall health of 
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diarthrodial joints and serves to protect the joint by re-
ducing friction between surfaces and absorbing impact 
(251). It is primarily composed of an ECM and chon-
drocytes (251). Varying ratios of collagen fibers, ECM, 
and chondrocytes contribute to the superficial, middle, 
deep, and calcified zones of cartilage (271). Cartilage 
has several known healing mechanisms. The cellular re-
sponse involves progenitor cells at the cartilage surface, 
as well as MSCs recruited from the synovial fluid and 
membrane (272). In addition, there is another cellular 
response that can occur from beneath the cartilage, 
which is mediated through the bone marrow (273). 
More recently, the connection between the cartilage 
health, local microenvironment, and the interaction 
with cell-based therapies have been explored (270).  
Injury to cartilage can naturally expose the sub-
chondral bone marrow, which contains various cellular 
components, such as MSCs and a variety of growth 
factors that assist in healing and repair (273-275). One 
of the most important functions of MSCs is directing 
chondrogenesis through paracrine activity, which re-
duces cell apoptosis and inflammation, while activat-
ing cell proliferation and mobilization (276). For an 
isolated cartilage lesion to heal in which there has been 
no subchondral plate exposure, there must be natural 
communication between the cartilage and bone mar-
row through channels in the subchondral plate (268). 
The formation of sclerosis and calcification of cartilage 
in osteoarthritis can interfere with this communication, 
as can an increase in fatty marrow (277). However, in 
acute trauma to the cartilage with a normal subchon-
dral plate, blood flow via healthy subchondral fenes-
trae is drastically increased in the cancellous bone to 
assist in the healing process. Madry et al (199) demon-
strated that MSCs from the nearby subchondral bone 
are subsequently mobilized, migrate to form a clot, and 
differentiate into chondrocytes/osteoblasts, which over 
time form repair tissue to fill the defect.  
In addition to cellular components, cartilage 
repair also involves growth factors such as fibroblast 
growth factor (FGF), vascular endothelial growth factor 
(VEGF), insulin growth factor-1 (IGF-1), and transform-
ing growth factor beta, which all play different roles 
and are able to stimulate chondrocyte differentiation 
of MSCs, increase chondrocyte proliferation, as well 
as decrease the catabolic effects of cytokines, such as 
interleukin-1 (IL-1) and MMPs (278).
Undifferentiated bone marrow MSCs can be seen 
at the chondral lesion by day 7 post injury and a carti-
laginous matrix at day 10 (199). At 6 weeks, the chon-
dral lesion is fully populated with fibrocartilaginous 
cells and chondrocytes (199). Any traumatic injuries to 
the subchondral plate are reestablished by 24 weeks 
when the majority of cartilage healing has taken place, 
replacing cancellous bone with the lamellar bone (199).
Surgeons have developed surgical techniques 
utilizing bone marrow as a natural reservoir of carti-
lage healing cells for decades. The microfracture and 
microdrilling techniques used to treat cartilage lesions 
create holes in the subchondral plate to release adja-
cent bone marrow, which initiates a healing response 
in osteochondral injury (268,269). These procedures 
have been shown to cause fibrocartilaginous healing 
that can provide a return to normal function in select 
patients (279). However, the cartilage produced is type 
I cartilage and not the original type II hyaline cartilage. 
As such it is more friable. BMC therapy has been shown 
to produce type II cartilage.
Ligament  
Both intrinsic and extrinsic cellular mechanisms 
play a role in ligament healing. Evidence regarding the 
relationship of ligament healing to bone marrow can 
be found in dental models involving the periodontal 
ligament (PDL) (280). BM-MSCs have been shown to 
mobilize the injured knee’s anterior cruciate ligament 
(ACL) (281). In addition, the health of the underlying 
bone and the knee ACL ligament appear to be inter-
related (281). Similarly, surgeons have made use of this 
relationship by performing microfracture  at the ACL 
origin or insertion to liberate BM-MSCs to enhance liga-
ment healing (282). 
Ligaments are fibrous bands that attach bone to 
bone. The area where the ligament makes that connec-
tion is known as the enthesis. The cellular components of 
ligaments include fibroblasts, collagen, elastin, proteo-
glycans, glycolipids, and fibronectin, with fibroblasts be-
ing the predominant cell type and collagen fibrils a key 
structural feature (283). These fibrils are predominantly 
comprised of type I collagen and to a lesser extent type 
III collagen. Although considered relatively hypovascular, 
there are blood vessels found in close proximity to the 
fibrils, with penetrating vascular channels that provide 
nutrition (284). Ligamentous injury involves structural 
disruption of these penetrating vessels, in addition 
to the ECM. Cellular insult occurs, and similar to other 
tissues, a healing response comprised of inflammation, 
proliferation, and remodeling follows (249).  
Disrupted blood vessels result in localized bleeding 
and hematoma formation. The immediate response is 
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one of vasoconstriction of the injured vessels and the 
initiation of the coagulation cascade to achieve he-
mostasis. Hematoma and clot formation ensue, which 
are vital for a subsequently successful healing response 
(283-288). Platelets contained within the clot release 
a multitude of cytokines and growth factors, which 
promote vascular dilation and permeability, resulting 
in local edema and the recruitment of inflammatory 
mediators. Neutrophils and monocytes infiltrate the re-
gion, where they digest and remove necrotic tissue and 
debris, while also signaling for the infiltration of fibro-
blasts (251,283,285). Fibroblasts, along with numerous 
growth factors, direct the transition from inflammation 
to proliferation (251). Key features of proliferation 
include collagen deposition, new ECM production, and 
angiogenesis in an attempt to bridge the ends of a torn 
ligament. Type III collagen is the predominant collagen 
early in the healing process (251,285). Proliferation ulti-
mately gives way to remodeling. During this stage, the 
ECM is strengthened and further organized, with a shift 
from type III to type I collagen (251,285).
In the vast majority of knee cruciate ligaments, 
vascular channels at the ligament entheses form direct 
contact between the ligament and the underlying bone 
marrow (289). In addition, many entheses have a blood 
vessel that enters the bone situated underneath the 
part of attachment site that moves the least during 
joint motion. Ligament health and the status of the 
bone it inserts on are interrelated. For example, in one 
study showing bone cysts at ACL insertion sites, 82% 
demonstrated ligament pathology (290). Hence struc-
turally this connection demonstrates that the ligament 
has a relationship with the bone onto which it inserts.  
MSCs possess the ability to migrate to sites of in-
jury, and do so under the direction of a multitude of 
growth factors, cytokines, and chemokines known to 
be prevalent in the natural healing process of ligaments 
(212,285,291,292). Additionally, there is evidence that 
supports BM-MSCs as having a direct role in the natural 
healing response following ligamentous injury. Much 
of this evidence comes from dental literature investi-
gating the response to injury of the PDL, a structure 
that provides an attachment between the alveolar 
bone and root surface cementum, and which is com-
monly injured during root canal treatments (280,293). 
Multiple studies have analyzed the postinjury activity 
at the PDL via mouse models, with green fluorescent 
protein-labeled bone marrow (GFP+ BM) transplanted 
into experimental mice via injection through the tail 
vein (293-296). In each of these studies, GFP+ BM was 
observed to migrate to the PDL following injury (293-
296). In addition to demonstrating migration to the site 
of injury, 3 of the studies also indicated differentiation 
of the transplanted bone marrow into fibroblasts at 
the PDL injury site, thus suggesting that BM-MSCs are 
actively recruited to sites of ligamentous injury and dif-
ferentiate into fibroblasts, thus being directly involved 
in the natural healing process (293,294,296). 
In a study by Kaku et al (280), GFP+ BM was trans-
planted directly into the femoral bone marrow of 
recipient mice. Four weeks following transplantation, 
teeth containing PDL were either extracted and imme-
diately analyzed or immediately replanted, simulating 
injury to the PDL in the replantation group (280). In 
the extraction-only group, GFP+ BM-MSCs were de-
tected within the PDL, predominantly with perivascular 
localization near the bone surface of the PDL. In the 
replantation group, following replantation, GFP+ BM-
MSCs were detected in larger quantities and dispersed 
throughout the PDL. These findings suggest that bone 
marrow plays a direct role in the natural PDL postinjury 
response (280). Further, given that the GFP+ BM had 
been transplanted into femoral bone marrow, and thus 
located at a distance from the PDL, the study’s findings 
suggest that these BM-MSCs are released into systemic 
circulation to reach the target site (280). 
Other studies focused on the ACL have also pro-
vided evidence of a direct role for bone marrow in liga-
mentous injury response. Morito et al (297) aspirated 
synovial fluid from humans who had suffered ACL rup-
tures and found a significantly increased concentration 
of MSCs in the synovial fluid as compared with nonin-
jured controls. Although this study did not elucidate 
the origin of the MSCs, it clearly indicated an increase in 
response to the injury (297). A later study in ACL-injured 
rat models indicated, via flow cytometry, a significant 
increase in the MSC concentration in whole blood at 
3 days postinjury in injured rats versus control group 
(281). Though short of being confirmatory, the panel of 
cell-surface receptors used were chosen based on their 
ability to be used to identify BM-MSCs, and therefore 
suggested that BM-MSCs are actively mobilized in a sys-
temic fashion following injury to the ACL in rats (281). 
In a second arm of this study, additional rats were intra-
venously injected with fluorescently labeled BM-MSCs 
following ACL rupture (293). These labeled BM-MSCs 
were observed to actively migrate to the injured joint, 
providing further evidence that BM-MSCs migrate to 
the location of acute ligamentous injury (281). The fact 
that these BM-MSCs seemed to localize to the synovium 
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and myotendinous junction, as opposed to the actual 
ACL, may be explained by the ACL’s well-recognized 
poor self-healing potential (283,286,287).
Clinical studies in which local bone marrow cells are 
used to facilitate ligament healing are also important 
as they demonstrate the simple surgical methods, such 
as bone marrow stimulation, can release adjacent bone 
marrow capable of healing the tear (282). For example, 
Gobbi and Whyte (282) published a case series of ath-
letes with partial ACL tears who were treated with a 
local marrow stimulation procedure and who had ex-
cellent outcomes. Rodkey et al (298) also confirmed this 
local healing marrow-based ligament response with ex-
perimentally created PCL injuries in dogs. These studies 
clearly indicate that if a natural fracture were to occur 
simultaneously with the knee ligament injury, causing 
bone marrow to leak onto the damaged ligament, that 
the natural ligament healing response would be aug-
mented (282,298). Centeno et al (286,288) also demon-
strated improvements in pain and functional outcomes 
out to 3 years following percutaneous, fluoroscopically 
guided BMC injection into the ACL for treatment of 
grade 1, 2, and 3 tears with minimal retraction in a 2 
case series. 
In conclusion, the natural healing response follow-
ing ligamentous injury is like that of other tissues, with 
phases of inflammation, proliferation, and remodeling. 
Multiple cells and signaling molecules are involved in 
the process. Currently, available evidence suggests BM-
MSCs play an active role in this process, likely through 
increased migration via systemic circulation to the site 
of ligamentous injury. 
Tendon
There is a clear relationship between the tendon 
and the bone on which it inserts. Tendon healing in-
volves both intrinsic and extrinsic cellular factors (299). 
In addition, the health of the tendon has been tied to 
the underlying number of MSCs in the bone marrow 
of the insertion (300). Surgeons have taken advantage 
of this association by using natural local bone marrow 
cells, as well as BMC injections to improve the quality of 
surgical tendon repairs (301).   
Tendons have poor blood supply in certain regions 
and can be notoriously difficult to heal (302). Normal 
tendon healing involves both intrinsic and extrinsic cel-
lular mechanisms. These include local tendon-derived 
MSCs and progenitor cells, as well as cells recruited to 
the site of injury from the surrounding periphery (287). 
In a labelled bone marrow MSC mouse model, Kaji-
kawa et al (303) demonstrated that bone marrow MSCs 
entered the peripheral circulation and were recruited 
to the injured tendon at various times in the healing 
process. These worked synergistically with local tendon-
derived MSCs to repair the tendon injury (303). Tendon 
healing follows 3 main phases that occur with overlap 
and variations in duration (299). During the inflamma-
tory stage, monocytes, neutrophils, and macrophages 
travel to the injury site. Several days later, the prolifera-
tion stage involves the synthesis of type III collagen in 
the ECM and activation of local progenitor cells, fol-
lowed last by the remodeling stage during which type I 
collagen predominates to restore the tendon strength, 
orchestrated through a cascade of local growth factors 
(299).  
The relationship between the tendon and its un-
derlying bone do appear linked, similarly to the inter-
relation between cartilage and bone. Hernigou et al 
(304) found reduced levels of MSCs at the tendon-bone 
interface in patients with symptomatic rotator cuff 
tear. Considering this association, surgeons have used 
this natural relationship between tendon and bone by 
using marrow stimulation (304). In this technique, the 
surgeon drills holes in the bone at the tendon insertion 
to release natural bone marrow cells into the repair site 
to augment the healing process (305-307). Effectively, 
this allows direct access of these cells to the damaged 
tendon rather than the cells mobilizing to the periph-
eral circulation and then to the area being repaired, 
which would only occur if a blood supply existed in this 
poorly vascularized injury region.  
In addition to creating channels from the bone 
marrow to the tendon to enhance the healing process, 
BMC taken from other areas can also enhance tendon 
healing (133,304). It has been demonstrated that in-
jecting BMC into surgical rotator cuff tendon repairs 
halves the retear rate of those tendons (133). This is also 
supported by animal models, which demonstrate that 
higher failure to load and enhanced tendon-to-bone 
healing is observed in tendons treated with BMC and 
surgical repair (308). Finally, partially torn rotator cuff 
tendons injected with BMC showed improved pain and 
function versus those treated by physical therapy alone 
(309).  
Muscle
Muscle has several self-repair mechanisms, both 
intrinsic and extrinsic. This includes local satellite cells 
and cells recruited from other areas, including the bone 
marrow (251). One rationale for supplementing muscle 
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repair is that it is often imperfect, with many animal 
models demonstrating bone marrow MSCs can assist in 
the repair process (310).
Like other musculoskeletal tissues, skeletal muscle 
follows 3 phases of muscle tissue repair: the initial 
inflammatory phase, followed by a repair phase, and 
finally a remodeling phase (311,312). The inflammatory 
phase starts with the initial muscle rupture, hematoma 
formation, and muscle necrosis, which triggers the 
complement cascade and recruitment of neutrophils 
and macrophages to the site of injury. These cells 
phagocytose and digest the damaged tissue and cel-
lular debris while releasing cytokines (tumor necrosis 
factor (TNF)- alpha, IL-1, IL-6 and IL-8, as well as IGF-1) 
that recruit additional inflammatory mediators and 
also signal resident satellite cells to proliferate (313). 
In the repair phase, M2 macrophages promote satel-
lite cell differentiation into new myoblasts (312). These 
myoblasts will subsequently bind to one another or to 
existing myofibrils to fill the muscle defect. At the same 
time, MSCs will communicate via paracrine signaling 
with the surrounding environment, recruiting fibro-
blasts, which will attempt to bridge the defect with 
dense scar, and prompting new blood vessel and nerve 
growth, via the secretion of numerous growth factors 
(IGF-1, hepatocyte growth factor, FGF, VEGF-A, brain 
derived neurotrophic factor, etc.) and immunomodula-
tory cytokines, which ultimately provides the building 
blocks for muscle regeneration (314-316). The last 
phase in muscle injury is the remodeling phase charac-
terized by reorganization of both scar and myofibers 
to ultimately optimize efficient force production. It has 
been shown that MMPs can digest fibrotic scar tissue 
and signal an influx of new progenitor cells, capable 
of further differentiation into new myofibers (313,317).  
Muscle fibers do not multiply, rather they are re-
paired and maintained by many neighboring cell types 
throughout adult life (318). It has been demonstrated 
that satellite cells, which lie adjacent to muscle fibers 
along the basement membrane are mitotically active, 
capable of self-renewal, and possess the ability to dif-
ferentiate into myonuclei, which replace the damaged 
muscle fibers (319). Satellite cells were traditionally 
thought to be the primary myogenic stem cell equiva-
lent, responsible for muscle regeneration and main-
tained entirely by self-renewal, however, this has been 
called into question as others have found that several 
other neighboring progenitor cells, such as endothelial-
associated cells, interstitial cells, and BM-MSCs, also 
function to maintain and replete the satellite cell pool 
(319). In response to skeletal muscle injury, BM-MSCs 
react by mobilizing through the peripheral circula-
tion, ultimately differentiating into both functioning 
satellite cells and new myofibers (320,321). Thus the 
relationship of bone marrow progenitor cells and their 
importance in supporting the muscle satellite cell pool 
is thought to be crucial to normal muscle tissue repair.  
The muscle repair process is often imperfect in 
the injury model. New muscle fibers have been found 
to have various structural abnormalities, can deposit 
themselves outside of the basal lamina, and can form 
aberrant attachments to the surrounding scar tissue, 
all of which can result in functional impairment of the 
new muscle tissue (322). Thus emerging concepts in the 
treatment of muscle injury focus on augmentation of 
the natural inflammatory and repair mechanism dis-
cussed earlier, with BM-MSCs to the site of injury. It is 
well documented in the cardiac literature that autolo-
gous transplanted bone marrow cells can be used to re-
generate portions of infarcted myocardium (323-326). 
In a rat crush injury model, local injection of BM-MSCs 
to injured muscle was shown to increase postinjury 
muscle contractile force when compared with injection 
with saline (327). Winkler et al (328) demonstrated a 
dose-response relationship to the administration of 
BM-MSCs, which resulted in greater maximum twitch 
strength and tetanic contraction force. It was shown 
by Natsu et al (329) that implantation of BM-MSC into 
rat tibialis anterior muscles following laceration injury 
promoted myofiber maturation and return to baseline 
contractile force. 
It is clear that the muscle repair mechanism is 
similar to that of tendon, cartilage, and bone with 
phases of inflammation, repair, and remodeling, which 
function to restore myofiber structure and function to 
best produce efficient force production. There is ample 
evidence suggesting that BM-MSCs function is not only 
to replace depleted muscle satellite cells, but is also 
to differentiate into new myofibers in vivo. They also 
possess the capability to both migrate to nearby sites 
of injury, as well as distant injuries via the circulation. 
As such, there is increasing interest in regenerative 
musculoskeletal treatment strategies that augment this 
natural muscle repair mechanism through additional 
supplementation of BM-MSCs into an area of muscle 
injury.  
The Spinal Joint Complex and Disc 
Spinal pain is the most common condition of all 
chronic pain conditions. Based on the available evi-
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dence, lumbar intervertebral discs, facet joints, sacroili-
ac joints, ligaments, fascia, muscles, the nerve root and 
its dorsal root ganglion, and the dural sleeve have all 
been shown to be capable of transmitting pain in the 
spine with resulting symptoms of spinal pain, chest wall 
pain, and extremity pain (1-9,12,138,151-154). Spinal 
pain is a complex and multifactorial entity, encompass-
ing mechanical, physiological, and psychosocial dimen-
sions. Genetic predisposition and environmental factors 
including smoking, obesity, and abnormal mechanical 
loading have been implicated in the pathogenesis of 
low back pain (1-5,12). Based on the theory of the struc-
tural basis of spinal pain, coupled with advances in im-
aging and increased understanding of the mechanisms 
of pain, there is increasing evidence that a significant 
proportion of low back pain is associated with degen-
erative disease of the spine involving spinal joints and 
the disc. Studies have shown that osteoarthritis of the 
spine with involvement of facet joints and degenera-
tive disc disease provide direct mechanistic association 
with spinal pain due to nociceptive nerve in growth oc-
curring in the painful degenerative intervertebral discs, 
as well as into osteoarthritis of the arthritic facet joints 
and sacroiliac joints (138).
Apart from the sacroiliac joint, which is a true syno-
vial joint, the spine consists of a 3-joint complex (the ar-
ticular triad), which is the basic anatomic and functional 
unit of the spine, consisting of the intervertebral disc 
and 2 symmetrical facet joints, which connect the adja-
cent vertebrae (3,4,138,330-348). Many biomechanical 
studies have demonstrated that the intervertebral disc 
and the 2 adjacent facet joints carry loads together in 
the normal lumbar spine (335). Multiple studies have 
demonstrated that the intervertebral disc is the initial 
site of spinal degeneration and that the adjacent facet 
joint degenerates as a result of disc degeneration (337-
339,347). However, other studies have indicated that 
disc degeneration does not necessarily precede facet 
degeneration (340-343). Consequently, it is quite likely 
that the intervertebral disc and facet joints contribute 
as a unit to the degenerative process (341,344,345). Lv 
et al (346) concluded that there was a significant corre-
lation between endplate defects, Modic magnetic reso-
nance imaging (MRI) signal changes, disc degeneration, 
facet tropism, facet orientation, and low back pain.
Although facet joints are true synovial joints, in-
tervertebral discs are composed of an annulus fibrosus, 
nucleus pulposus, and cartilaginous endplates (349). 
During the process of degeneration, discs undergo mor-
phologic changes with tears and dehydration. They also 
undergo changes in the molecular composition of their 
structure such as apoptosis, accumulation of debris with 
decreased diffusion of waste products, and decreased 
proteoglycan synthesis (349). The molecular changes 
are components of disc degeneration, which can lead 
to spinal stenosis, radiculopathy, myelopathy, and me-
chanical low back pain. Facet joint arthritis is a clinical 
and pathological process that involves the functional 
degeneration of the synovial facet joints. Even though 
it is viewed as a disease of articular cartilage loss and 
bony hypertrophy, the process of degeneration actu-
ally involves the whole joint, including the subchondral 
bone, cartilage, ligaments, capsule, synovium, and 
periarticular paraspinal muscles and soft tissues (347). 
As described earlier, in the 3-joint complex, the inter-
vertebral disc and the facet joints degenerate together.
Degenerative vertebral endplate and subchondral 
bone marrow changes were first noted on MRI by 
de Roos et al (350) in 1987. These MRI changes were 
formally classified in 1988 by Modic et al (351). Type 
1 Modic change is defined as a hypointense signal of 
the vertebral endplate and body on the T1 images 
and hyperintense on T2 images, especially on the STIR 
sequence. This signal change represents bone marrow 
edema and inflammation and is associated with disrup-
tion and fissuring of endplates and the formation of 
fibrovascular granulation tissue. These changes reflect 
the inflammatory stage of disc degeneration. Type 2 
Modic change is defined as a hyperintense signal of the 
vertebral endplate and body on the T1 images and hy-
perintense on nonfat suppressed T2 images. This is a re-
sult of the conversion of normal red hemopoietic bone 
marrow into yellow fatty marrow as a result of marrow 
ischemia. Modic type 3 changes are hypointense on 
both T1 and T2 secondary to subchondral bone sclerosis. 
Modic 1 and 2 changes are much more prevalent than 
Modic 3, and these changes are most commonly seen 
at the L4, L5, and S1 levels next to degenerated discs. 
Modic changes are uncommon in asymptomatic indi-
viduals without degenerative disc disease (352). Kok-
konen et al (353) have shown that, based on MRI and 
computed tomography discography, there is a strong 
correlation between vertebral endplate changes and 
disc degeneration (346). The edema producing Modic 
1 signal changes are secondary to microfractures of the 
endplates and contiguous cancellous bone. There is an 
increase in vascular density, in the number of nerve 
endings due to nociceptive ingrowth, and in the levels 
of proinflammatory chemical mediators, with these 
vascular and inflammatory changes following the initial 
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mechanical phenomena (352). Ohtori et al (354) found 
that inflammatory cytokines and nerve ingrowth into 
vertebral endplates may be a cause of discogenic low 
back pain and that Modic type 1 changes, representing 
more active inflammation, seem to be mediated by pro-
inflammatory cytokines, whereas type 2 and 3 changes 
are more quiescent stages of the process. Kjaer et al 
(355) has demonstrated that degenerative disc disease 
by itself is a fairly benign condition, whereas degen-
erative disc disease with Modic changes is much more 
frequently associated with clinical symptoms. Among 
Modic changes, type 1 changes are the ones most 
strongly associated with low back pain (352). Mitra et al 
(356) has found that type 1 Modic changes are dynamic 
lesions that, in most cases, either increase in size or con-
vert into type 2 changes. They have also demonstrated 
that the evolution of type 1 Modic changes into type 
2 changes result in the improvement of symptoms. In 
addition, they observed that patients in whom type 1 
changes increased were clinically worse. Finally, various 
types of Modic changes can coexist with each other in 
the same vertebrae (330). 
BMC in the Spine
The intervertebral disc and the bone marrow locat-
ed in the vertebral body are in constant communication 
in the same way that cartilage and subchondral marrow 
in all joints (including the facet joints) make up one bio-
logic unit. The spine also contains ligaments and muscles, 
and the earlier described principles of homology would 
apply to those structures as well, meaning that bone 
marrow is homologous to the functional spinal unit. 
The vertebral bone marrow and the intervertebral 
disc are in constant communication to maintain the 
health of that structure. For example, Dudli et al (332) 
found that in intervertebral discs with Modic changes, 
fibrogenic and pro-inflammatory cross talk between 
the vertebral bone marrow and adjacent disc is a critical 
part of the disease process. In addition, other authors 
have found that the degenerative processes in the disc, 
endplate, and bone marrow are highly associated (334). 
In a recent MRI diffusion study, the lack of bone mar-
row perfusion across the endplate was associated with 
degeneration of the intervertebral disc (336). Hence 
the status of the bone marrow in the vertebral body 
impacts the health of the disc, meaning that the verte-
bral bone marrow and the intervertebral disc are one 
homologous biologic unit.
Increases in the level of high-sensitivity C-reactive 
protein in patients with low back pain and Modic type 
1 changes indicate local inflammation in vertebral end-
plates. The same is not shown for Modic type 2 and type 
3 changes. However, it is now clear that subchondral 
bone sclerosis and endplate fissuring is present in all 
types of Modic changes. The different Modic types 
are believed to represent different stages of the same 
pathological process. Modic changes can convert from 
one type to another, most commonly from type 1 to 
type 2. Type 1 can also be reversed to normal only if the 
underlying mechanical and molecular abnormalities are 
resolved, which is very rare. Modic type 2 is more stable. 
Rarely, type 2 will convert to type 3. There is evidence 
to suggest that patients with an increased tendency 
to inflammation and changes in bone marrow at the 
vertebral endplates also have an increased tendency to 
develop long-term back pain (357).
The endplate is the primary pathway for transport 
between vertebral capillaries and the many cells within 
the annulus and the sparse cells within the disc nucleus. 
Blood vessels and marrow spaces abut the cartilaginous 
and cortical bone layer of the endplate, providing chan-
nels for glucose and oxygen to enter the disc and for 
waste products to exit the disc. 
BMC therapies in intervertebral disc degeneration 
repopulate the intervertebral disc and restore func-
tional tissue through matrix synthesis by implanted 
cells and potentially beneficial influences on native 
cells (3,79,80,82-87,98,105-107,349). Stem cells serve 
as a source to replace the nonviable cells of the an-
nulus fibrosus and nucleus pulposus (349). Autologous 
nucleus pulposus cell reimplantation has been shown to 
retard degenerative changes in a dog model (358,359); 
however, as the nucleus pulposus is relatively hypocel-
lular, harvesting sufficient cells for reimplantation may 
result in injury to the disc. Further, nucleus pulposus 
cells from degenerated discs display, premature senes-
cence  and a catabolic metabolism (334,337,359-361), 
which make them unsuitable for transplantation in 
which normal cell function is required. Thus MSCs have 
been proposed as an ideal cell source of regeneration. 
An increasing number of studies have demonstrated 
the ability of BM-MSCs to differentiate into nucleus 
pulposus-like phenotype (discogenic differentiation). 
The literature has shown that BM-MSCs can differen-
tiate into osteoblasts, adipocytes, chondroblasts, and 
cells having the phenotypic features of the interver-
tebral disc under proper in vitro conditions (362-364). 
Further, the capability of BM-MSCs to differentiate into 
nucleus pulposus-like cells and their ability to stimulate 
production of a new cell matrix has been described 
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(365). This hypothesis was tested by Mochida et al (366) 
for intervertebral disc repair with activated nucleus 
pulposus cell transplantation over a 3-year prospective 
clinical study of its safety. Multiple other investigators 
also have studied the results of implantation of MSCs 
(87,366-371).
In vivo studies have also demonstrated the abil-
ity of implanted MSCs to enhance matrix production, 
particularly glycosaminoglycan synthesis, resulting in 
increased disc height and hydration (372-377). Early 
studies on discogenic differentiation of MSCs relied on 
the fact that nucleus pulposus cells are chondrocyte-like 
and express chondrogenic markers, such as SOX-9, type 
II collagen, and aggrecan (378). In preclinical studies of 
the use of stem cells in the spine (379-381), adult stem 
cells derived from bone marrow showed promise for 
both osteogenesis and chondrogenesis. Further, various 
growth factors and scaffolds have also been shown to 
enhance the properties and eventual clinical potential 
of these cells.
The descriptions of immunomodulation of MSCs in 
discogenic pain by Miguélez-Rivera et al (382) showed 
that conditioned media from MSCs downregulated 
the expression of various proinflammatory cytokines 
produced in the pathogenesis of discogenic pain, such 
as IL-1, IL-6, IL-17, and TNF. Discogenic cells generated 
from different adult human donors were also evaluated 
for surface marker expression profile, matrix deposi-
tion, and tumorigenic potential (383). Subcutaneous 
injection of discogenic cells into nude mice to assess 
cell survival and possible ECM production in vivo, and 
assessment of therapeutic potential of discogenic cells 
after disc injury in a rabbit model of disc degeneration 
showed that discogenic cells have a consistent surface 
marker profile, are multipotent for mesenchymal 
lineages, and produce ECM consisting of aggrecan, 
collagen 1, and collagen 2 (383). This study concluded 
that intradiscal injection of discogenic cells may be a 
viable treatment for human degenerative disc disease 
with production of ECM that may rebuild the depleting 
tissue within the degenerated discs without any signifi-
cant safety concerns.
The role of MSCs in healing and regeneration 
by studying autologous BMC MSC migration into the 
injured intervertebral disc has been investigated (384-
389). MSC homing has been reported to play a role in 
the endogenous regeneration of different skeletal tis-
sues, including bone and cartilage. In vivo, this process 
is tightly controlled by a gradient of signalling mol-
ecules. In the intervertebral disc, recruitment of bone 
marrow cells toward the regenerating intervertebral 
disc has been demonstrated in a mouse tail model in 
vivo. However, the findings from the intervertebral disc 
degeneration model suggests that the pool of available 
cells or their recruitment efficiency may need to be en-
hanced by exogenous means to achieve a significant re-
generative effect (384). Thus, migration of exogenously 
delivered BM-MSCs through the endplate into the 
intervertebral disc has been described as an alternative 
approach for intradiscal cell treatment in several whole 
intradiscal organ culture models (388-391). Wangler 
et al (384) in an experimental study with human MSC 
and intervertebral disc tissue samples showed that MSC 
homing was involved directly in the maintenance of the 
human intervertebral disc (392).   
Wang et al (83), in a systematic review and meta-
analysis of controlled trials using animals to investigate 
the efficacy of intervertebral disc regeneration with 
stem cells, demonstrated that stem cells transplanted 
into the intervertebral discs of quadripedal animals de-
celerate or arrest the intervertebral disc degenerative 
process. In another systematic review of comparative 
controlled studies regarding the potential benefits of 
using MSCs in disc degeneration, Yim et al (393) showed 
that bone marrow MSCs produced a significant inhibi-
tion of disc degeneration with a better quality of repair 
compared with non-MSC treatments.
Bone marrow MSCs that can be altered genetically 
to express specific genes and differentiate into terminal 
cells used in bone fusion are also currently being inves-
tigated for spine fusion. Comparisons are made to local 
or harvest autografts (349,394). In vivo experiments 
involve the injection of genetically engineered MSCs 
that express recombinant human bone morphogenic 
protein into sites for spinal fusion (395). BMC MSCs with 
the ability to differentiate into adipocytes, osteoblasts, 
and chondroblasts continue to proliferate, providing 
an important source of bone formation to enhance 
the spinal fusion (124,396). However, the therapeutic 
potential of BMC MSCs is curtailed by the small number 
of osteoprogenitor cells (397). Consequently, selec-
tive cell retention technology has been described as a 
novel method to enrich the graft material with BMC 
MSCs obtained with bone marrow aspiration through a 
simple and effective method for intraoperative concen-
tration of MSCs without the need for ex vivo expansion 
that improves the characteristics of the graft material 
(398,399). Further, a study of long-term radiologic and 
clinical outcome after using bone marrow MSC concen-
trate obtained with selective retention cell technology 
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in posterolateral spinal fusion showed a fusion rate of 
100% (396). This is in contrast to nonunion rate of 25% 
to 30% and pseudoarthrosis of 23% to 44% (400,401), 
with the incidence of reoperation following lumbar 
fusion surgery of 20.1% (402). Multiple other studies 
have been published showing increased levels of fusion 
(394).
clInIcal outcoMes
BMC-MSCs are utilized in managing all types of 
musculoskeletal conditions, including for spine regen-
eration and fusion.
A literature search was carried out utilizing mul-
tiple databases. The literature search  involved bone 
marrow stem cell research with key words of BMC and 
BMC implant into various musculoskeletal and spine 
structures. A total of 3,488 manuscripts were identified 
through December 2019. 
Spine 
BMC is utilized for multiple types of interventions 
in the spine, including intraarticular injections of fac-
ets and sacroiliac joints, disc injections, and epidural 
injections.
Disc Injections 
An overwhelming majority of the research with 
BMC stem cells is focused on the lumbosacral spine. 
Navani et al (3) published guidelines based on appro-
priate search criteria, study selection, methodologic 
quality assessment, and analysis of evidence that in-
cluded qualitative, as well as quantitative, analysis with 
conventional dual arm and single arm meta-analysis. 
Navani et al (3) identified 5 systematic reviews (79,83-
86). The overall majority of the studies used BM-MSCs, 
concluding that BM-MSCs were the gold standard.
Khan et al (84) studied not only intervertebral disc 
repair and spinal fusion, but also spinal cord injury. This 
review identified almost 2,600 manuscripts; however, 
only 53 met eligibility criteria. Of these, there were 28 
studies on intervertebral disc repair and 9 studies on 
spinal fusion. This systematic review concluded that 
MSCs were a very good source for treatment of spinal 
conditions. 
Wu et al (86) reported the results of 6 studies with 
a 44.2 point decrease in the pooled mean difference 
in pain scores, and a 32.2 point pooled mean differ-
ence in the Oswestry Disability Index with no adverse 
effects. In this systematic review, 3 studies used stem 
cells (369,403,404) and 3 studies used chondrocytes 
(87,366,368). The mean follow-up time among the 
6 trials was 22 months. In this analysis, they reported 
that one study found improvements in the disc contour 
or height posttreatment (368). Another study showed 
increase in the fluid content of the discs at 12 months 
(369). 
Basso et al (85) in a systematic review identified 
4 manuscripts (366,369,403,405) that involved the use 
of stem cells. All of the studies reported that the in-
tradiscal injection of stem cells was safe with variable 
effectiveness. 
Sanapati et al (79) in a systematic review of 26 man-
uscripts, included 7 studies utilizing stem cells (87,367-
404,406,407) with one study having 3 publications. The 
results showed level III evidence for disc injections of 
MSCs, and level IV evidence for epidural injections, lum-
bar facet joint injections, and sacroiliac joint injections, 
with qualitative and quantitative synthesis of evidence 
using conventional and single-arm meta-analysis. Ap-
pendix Table 1 shows the characteristics of the included 
studies of stem cell therapy in disc degeneration as 
stated in ASIPP guidelines that were derived from the 
systematic review of Sanapati et al (79).
Sanapati et al (79) in a single-arm meta-analysis, 
as shown in Fig. 6, showed changes in the pain scores 
(87,354,368,369,371,406). The pooled mean differ-
ence in the decreased pain scores from baseline to the 
12-month follow-up was 36.943 points (95% confidence 
interval [CI]: -49.855 to -24.030, P < 0.001). Heteroge-
neity across the studies was high (I2 = 86%). They also 
showed changes in the functional scores, as shown in 
Fig. 7. Six studies reported on outcome assessment over 
a period of 12 months (87,368,369,406,407). The pooled 
mean difference in the decreased disability scores from 
baseline to the 12-month follow-up was 26.342 points 
(95% CI: -32.359 to -20.325, P < 0.001). Heterogeneity 
across the studies was moderate (I2 = 55%).
Based on multiple systematic reviews (79,83-86), 
as well as randomized and nonrandomized studies 
included in systematic reviews and guideline develop-
ment (3,87,354,366-407), there is level III evidence for 
intradiscal injections of BMC.
Spinal Fusion 
For a variety of spinal disorders, including trauma, 
deformity, tumors, infection, instability, and degen-
erative spine disease, the rate of spinal fusion has been 
increasing at an escalating pace (396). However, fol-
lowing fusion, repeat surgery was shown to be present 
in approximately 20% of the patients (402), pseudoar-
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throsis after posterolateral lumbar fusion varying from 
23% to 44% (400,401), and nonunion in 25% to 30% 
depending on the procedure (394). Shah and Hsu (394) 
reviewed all of the studies available using autologous 
MSCs (n = 11) from bone marrow aspirate. Overall, the 
studies have shown increased fusion rates as high as 
100% (396,408-412). 
Facet Joint Intraarticular Injections
Facet joints are true synovial joints and have been 
proven to cause neck, upper extremity, mid back, upper 
back and chest wall, and low back and lower extremity 
pain (138). The majority of the literature of biologics is 
based on intraarticular injections in the lumbar spine of 
platelet-rich plasma (PRP), which have been shown to 
have positive results (79). Controlled diagnostic studies 
have shown the prevalence of facet joint pain in 36% 
to 67% in the cervical spine, 34% to 48% in the tho-
racic spine, and 27% to 41% in the lumbar spine based 
on controlled comparative local anesthetic blocks in 
patients without disc herniation or radiculitis (138,412-
416). Based on the results of PRP injections (79), the 
Fig. 6. Changes in pain score (Numerical Rating Scale or Visual Analog Scale, 0-100) after treatment (12 months follow-up 
data) of  cell therapy of  lumbar disc.
Adapted from: Sanapati J, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review and 
metaanalysis. Pain Physician 2018; 21:515-540 (79).
 
Fig. 7. Changes in Oswestry Disability Index after treatment (12 months follow-up data) of  cell 
therapy of  lumbar disc.
Adapted from: Sanapati J, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review 
and metaanalysis. Pain Physician 2018; 21:515-540 (79).
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results with BMC are expected to be equivalent or su-
perior to PRP injections. 
Sacroiliac Joint 
The sacroiliac joint is a true synovial joint and has 
been proven to cause low back and lower extremity pain 
(138,417). Diagnostic studies have shown the prevalence 
of sacroiliac joint causing low back pain in approximately 
10% to 25% of patients (138,417). Even though there is 
extensive literature discussing the use and effectiveness 
of biologicals in the management of peripheral joint 
pain, similar to facet joints, there is no literature on sac-
roiliac joint injections with BMC. However, based on the 
results of PRP injections (79), the results with BMC are 
expected to be equivalent or superior to PRP injections, 
which have been shown to have positive results. 
Epidural Injections
Epidural injections are performed to treat vari-
ous types of spinal and extremity pain secondary to 
disc herniation, nerve root irritation, discogenic pain 
with radiation into the extremity, spinal stenosis, and 
the postsurgery syndrome (138,418-422). There is vast 
literature regarding the effectiveness of various mo-
dalities in managing discogenic and nerve root pain 
(138,418-422). The effects of epidural injections of PRP 
have been studied; however, there are no studies show-
ing the effects of epidural BMC.
Knee
Multiple publications of systematic reviews, ran-
domized controlled trials, and continuing research, 
show that injections of BMC or isolated bone mar-
row and MSCs show promise as a safe and effective 
treatment for multiple knee conditions (88,109-
111,134,239,421-433). A recent systematic review by 
Migliorini et al (109), assessing the stem cell injections 
for knee osteoarthritis identified 18 studies, comprising 
1,069 treated knees. BMC-MSCs were administered in 
72% of the included studies with a mean Visual Ana-
log Scale score improvement from 18.37 to 30.98 and 
36.91 at 6- and 12-month follow-up, respectively. The 
evaluation also showed improvement in functional 
scores with improvement in the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) 
score from 25.66 to 25.23 and 15.6 at 6- and 12-month 
follow-up, respectively. The mean walking distance 
improved from 71.9 to 152.22 and 316.72 at 6- and 
12-month follow-up, respectively. Multiple other scores 
also improved significantly. The authors have concluded 
that according to the current evidence BMC infiltration 
for knee osteoarthritis can represent a feasible option, 
leading to an overall remarkable improvement of all 
clinical and functional outcomes. Further, they have 
also shown that patients treated at earlier degenera-
tion stages reported statistically significant better out-
comes (134,229,232,233,239,423-433). Table 5 shows 
Table 5. Overall results of  the comparisons of  MSC injections for knee osteoarthritis with 72% of  included studies injected BMC.
Outcome
Baseline 12 months
Estimated effect, IV, Random 
(95% confidence interval)
Mean (SD) Mean (SD) 0-12 Months P
VAS score 55.28 (18.37) 20.08 (91.54) 36.91 (30.36 to 43.43) < 0.0001
WOMAC 25.66 (15.10) 24.98 (14.39) 15.60 (10.10 to 21.10) < 0.0001
Walking Distance 71.90 (28.41) 57.33 (270.31) 316.72 (-696.54 to 63.10) 0.10
Lequesne Scale 33.76 (19.72) 20.70 (19.07) 12.90 (-1.35 to 27.15) 0.08
KOOS
Overall 41.07 (12.17) 65.13 (13.56) 18.94 (27.00 to 10.88) < 0.0001
Symptoms 51.27 (15.21) 69.57 (14.99) 14.14 (21.35 to 6.93) 0.001
Pain 49.55 (14.51) 69.57 (14.99) 22.03 (29.39 to 14.67) < 0.0001
Function 50.36 (18.90) 76.87 (16.02) 21.54 (28.84 to 14.24) < 0.0001
Recreation 27.84 (17.46) 57.97 (21.17) 23.07 (32.10 to 14.04) < 0.0001
Quality of Life 32.69 (23.40) 54.87 (17.07) 14.07 (38.98 to -10.84) 0.27
VAS = Visual Analog Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; KOOS = Knee injury and Osteoarthritis 
Outcome Score.
Adapted from: Migliorini F, Rath B, Colarossi G, et al. Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: Results 
at 12-months follow-up: A systematic review of the literature. Arch Orthop Trauma Surg 2019 [Epub ahead of print] (109).
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the comparisons of outcomes after MSC injections for 
knee osteoarthritis, published in the systematic review 
by Migliorini et al (109).
There have been multiple other systematic re-
views (88,110,111,134,434). Ha et al (111) performed 
a systematic review assessing intraarticular MSCs for 
the osteoarthritis of the knee along with evidence of 
cartilage repair including  a total of 17 studies, with 
8 studies (229,232,233,237,239,424,425,433,435,436
) using bone marrow derived MSCs. They concluded 
that intraarticular MSCs provided improvement in pain 
and function in knee osteoarthritis with follow-up of 
less than 28 months in many cases. They also showed 
efficacy of MSCs for cartilage repair in osteoarthritis. 
However, they concluded that evidence of efficacy of 
intraarticular MSCs on both clinical outcomes and car-
tilage repair was limited to level III evidence. Table 6 
shows the characteristics and clinical outcomes of the 
studies of osteoarthritis using BMC.
Chahla et al (88) also performed a systematic re-
view of outcomes of the concentrated bone marrow 
aspirate for the treatment of chondral injuries and 
osteoarthritis of the knee. They identified 8 studies 
evaluating the efficacy of BMAC on focal cartilage in-
juries (430-433,435-445), and 3 studies evaluating the 
clinical efficacy of BMAC in the treatment of osteoar-
thritis (430,437,446). All 11 studies with patients having 
osteoarthritis and chondral effects reported good to 
excellent overall outcomes with the use of BMAC. 
Cavinatto et al (434) in a systematic review and crit-
ical analysis in animal and clinical studies of assessing 
the role of BMAC for the treatment of focal chondral 
lesions of the knee reported the results of 13 clinical 
studies. Overall, all clinical studies, independent of the 
study group or level of evidence, reported improved 
clinical outcomes and higher macroscopic, MRI, and his-
tology scores. However, clinical studies were scant and 
showed low scientific rigor, poor methodologic quality, 
and low levels of evidence on average.
In a systematic review of human studies of office-
based MSC therapy for the treatment of a variety of mus-
culoskeletal disease, Law et al (110) identified 8 studies 
Table 6. Clinical outcomes of  studies of  osteoarthritis using MSCs, with 8 of  17 studies using BMC.
Author











Wakitani et al (229), 
2002 24 (12/12) 63 15/9 NS 16 HSS
81.3 vs. 79.2 
No significant difference
Davatchi et al (231), 
2011 4 58 2/2 30.3 12
Pain VAS, walking time, 
number of stairs
Pain, walking time, and number of 
stairs to climb improved
Emadedin et al (232), 
2012 6 55 6/0 31.6 12
Pain VAS, WOMAC, 
walking distance All outcomes improved
Wong et al (237), 
2013 56 (28/28) 51 29/27
23.9 
(median) 24 IKDC, Lysholm, Tegner
All outcomes improved 
Better scores in the MSC group*
Orozco et al (234), 
2013 12 49 6/6 NS 12 VAS, WOMAC, SF-36 All outcomes improved
Vega et al (239), 2015 30 (15/15) 57 19/11 NS 12 VAS, WOMAC, Lequesne, SF-12
All outcomes improved 
Better scores in the MSC group*
Gupta et al (435), 
2016 60 (40/20) 56 45/15 27.8 12 VAS, ICOAP, WOMAC No significant differences in all groups
Lamo-Espinosa et al 
(433), 2016 30 (20/10) 61 11/19 28.4 12 VAS, WOMAC
All outcomes improved 
Better improvement in the MSC 
group* 
Much improvement in the high-dose 
group
BMI = body mass index; HSS = hospital for specific surgery; ICOAP = intermittent and constant osteoarthritis pain; IKDC = International Knee 
Documentation Committee; VAS = Visual Analog Scale score; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; SF-
36 = Short Form-36; SF-12 = Short Form-12; MSC = mesenchymal stem cell; NS = not specified; F/U = follow-up.
Adapted from: Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular mesenchymal stem cells in osteoarthritis of the knee: A systematic review of clini-
cal outcomes and evidence of cartilage repair. Arthroscopy 2019; 35:277-288 (111).
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with a total of 941 patients (228,236,406,430,447-450). 
Overall, they concluded that support in the literature is 
strongest for the use of BMAC injections for the treat-
ment of knee injuries.  
Two recent randomized controlled trials have also 
been published that use BMC injections to treat knee 
osteoarthritis. Centeno et al (451) published a random-
ized cross-over trial of high-dose BMC injected versus 
physical therapy showing excellent results compared 
with control. Gobbi et al (470-471) published a smaller 
group of patients who used low-dose BMC diluted with 
high volumes of platelet poor plasma and observed 
good results in both the osteoarthritis and saline con-
trol groups. 
BMC injection using fluoroscopic guidance has also 
been used to repair ACL injuries. Centeno et al (451) 
have published 2 case series with imaging outcomes 
showing evidence of healing both on MRI and with 
functional questionnaires (453,454). In these cases, 
similar to surgical results were obtained only through 
precise injection.
In summary, BMC demonstrated beneficial effects 
not only in knee osteoarthritis, but in the repair of ACL 
and other injuries involving cartilage and cortical bone.
Based on the evidence derived from multiple 
systematic reviews (88,109-111), relevant randomized 
controlled trials (229,231,232,234,237,239,430,433,435
,437,446), and multiple observational studies, there is 
moderate or level II evidence for treatment of knee os-
teoarthritis, there is level III evidence based on system-
atic reviews, randomized controlled trials, and obser-
vational studies of focal cartilage injuries (88,440,445).
Hip 
BMC has been shown to produce reasonable out-
comes for hip injections (108). Despite the emerging lit-
erature with overall hip injections, the literature related 
to implantation of autologous bone marrow stem cells 
compared with other modalities of treatments in osteo-
necrosis of the femoral head is significant (109,455). In 
fact, Wang et al (455) in a meta-analysis of core decom-
pression combined with autologous bone marrow stem 
cells versus core decompression alone for patients with 
osteonecrosis of the femoral head included 14 studies 
with 540 patients (456-469). They included studies from 
2004 to 2018. Further, studies were mainly published 
in Belgium and China. Results of meta-analysis showed 
the core decompression combined with bone marrow 
stem cells was superior in pain reduction at 6 months, 
12 months, and 24 months, and a decrease in number 
of hips undergoing total hip arthroplasty, the WOMAC 
score, and the volume of the postoperative necrotic 
zone. Among the multiple reports available, Centeno 
et al (470) evaluated 196 patients with hip osteoarthri-
tis treated with BMC percutaneous-guided injection. 
Patients reported relief of pain and better function; 
there were no severe or serious adverse events (470). In 
2006, the same authors (471) had already demonstrated 
a partial regeneration of a severely degenerated hip 8 
weeks after bone marrow aspirate injection; the results 
were confirmed by MRI. Chahla et al (472) described in 
a review article the successful use of BMC for hip osteo-
arthritis in their institution, with good clinical results 
and no adverse effects reported.
Regarding soft tissues injuries of the hip, there is a 
lack of publications showing BMC use in humans. How-
ever, there are several reports of bone marrow use on 
animals, some in other body parts, and a vast literature 
about PRP (108). Due to biological similarities between 
BMC and PRP, as well as the verified safety of the for-
mer, its use for this purpose must increase in the next 
years. Torricelli et al (473) demonstrated impressive re-
sults using a combination of BMC and PRP to treat over-
use injuries in competition horses, achieving an almost 
85% rate of return to competition. Campbell et al (474) 
treated a professional soccer player with capsular injury 
and tear of the gluteus minimus tendon using both 
BMC and PRP. They described improvement of pain and 
strength, as well as the morphologic changes on MRI.
Recent studies of hip osteonecrosis have dem-
onstrated that there is a decrease in the number and 
function of mesenchymal cells in the trochanteric re-
gion and in the femoral head of patients resulting in a 
limited healing capacity of the necrotic areas (470,471). 
Mononuclear cell transplantation appears to be a mini-
mally invasive technique capable of reducing pain and 
preventing the progression of these lesions (470-473).
Data show that after femoral head collapse, the 
rate of treatment failure increases greatly. Other fac-
tors that may impair biological treatment would be the 
use of corticosteroids and alcoholism (472-474).
The most common technique for grafting the 
mononuclear cell concentrate into the hip is through 
the decompression tunnels into the necrotic areas 
of the femoral head. The concentrate can be applied 
alone or in combination with a scaffold that guarantees 
mechanical support and the presence of the cells in the 
areas of necrosis (475-477). A few studies have used 
transplantation of mononuclear cells by selective cath-
eterization of the medial circumflex artery (450,478), or 
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the intravenous injection of mesenchymal cells betting 
on the ability of the cells to home in on injured tissues 
(479). 
The variation in the techniques of collection, con-
centration, and grafting shows the lack of uniformity of 
the methods, which leads to the difficulty of comparing 
the data in the literature.
Ankle 
The use of BMC for the treatment of osteochondral 
defects and osteoarthritis of the talus was reviewed by 
Chahla et al (480). In this systematic review, 4 studies 
that used BMC to augment a variety of surgical tech-
niques for the treatment of osteochondral lesions of 
the talus were analyzed.
Clinical improvement in Orthopaedic Foot and 
Ankle Society (AOFAS) score and MRI scan were ob-
served in 48 patients with posttraumatic type II lesion 
of the talar dome. These patients underwent a one-step 
arthroscopic technique for cartilage repair and treated 
with BMC and collagen powder or hyaluronic acid 
membrane as scaffolds for cells and platelet gel (481). 
The studies also showed that at 24 months follow-up 
new tissue was formed. The clinical outcomes were 
maintained in these patients for 4 years after treat-
ment, although there was a decline in the AOFAS scores 
between 24 and 48 months of follow-up (482).
Outcome measures were reported in Foot and 
Ankle Outcome Score and in Short Form-12 general 
health questionnaire in patients with lesions of the 
talus after autologous osteochondral transplantation 
with BMC (483).
Retrospective outcomes after osteochondral le-
sions of the talus treated with arthroscopy followed by 
talar bone marrow stimulation with and without BMC 
as a biological adjunct were analyzed in 22 patients 
(484). The results show that the use of BMC resulted 
in similar functional outcomes, but improved border 
repair tissue integration, with less evidence of fissuring 
and fibrillation on MRI.
The use of BMC for acute sports-related Achilles 
tendon rupture was demonstrated in studies with 27 
patients (485). In this group of patients, there were no 
adverse outcomes or reruptures.
Shoulder 
Poor microcirculation of the human rotator cuff 
results in chronic lesions that do not heal and tend to 
increase in size over time, increasing the number of 
symptomatic patients (108,486,487). 
Several experimental studies on the use of mesen-
chymal cells for the treatment of tendinopathies have 
shown encouraging results. The healing of the surgical 
repair occurs with the formation of fibro-cicatricial tissue 
of low quality. The use of BMC in the treatment of the 
rotator cuff aims to improve the quality of tendons and 
their healing (108). The BMC can be applied at the lesion 
site by direct injection or associated with scaffolds. 
In a clinical study (488) of rotator cuff repair using 
the mini-open technique with transosseous suture and 
application of bone marrow mononuclear cells, a full 
tendon reconstruction was observed in patients at 12 
months follow-up. In this study, the improvement of 
University of California at Los Angeles score (31 ± 3.2) in 
13 of 14 patients remained unchanged up to the second 
year follow-up.
The BMC outcomes were demonstrated in a group 
of 90 patients undergoing arthroscopic repair of the su-
praspinatus tendon (133). Half of the patients received 
BMC injection at the tenodesis site and half were in-
cluded in the control group (without BMC treatment). 
After 6 months of follow-up, the BMC group had 100% 
repair healing versus 67% in the control group. After 
10 years of follow-up, 87% of the cases in the BMC 
group still had intact tendon against 44% in the con-
trol group. Those patients in the treated group without 
intact tendons had received the lowest number of ap-
plied MSCs. Centeno et al (489) published a midterm 
analysis of a randomized crossover trial comparing per-
cutaneous BMC with platelet-product injection versus 
exercise alone treatment of partial or full nonretracted 
supraspinatus tears. Outcomes of the 25 patients who 
had reached 1 year follow-up showed significant im-
provements in pain at 3 and 6 months, and functional 
improvements at 3 months with the majority of post-
treatment MRI scan demonstrated decrease in tear size. 
No adverse outcomes were reported (489). 
A prospective study (490) was performed in pa-
tients with glenohumeral osteoarthrosis and in patients 
with lesions of less than 1.5 cm of the rotator cuff. Both 
groups were treated with an injection of BMC plus PRP 
guided by ultrasound or radioscopy. BMC/PRP treat-
ment led to significant improvement in the Disability of 
the Arm, Shoulder, and Hand score, and in the numeric 
scale of pain with subjective improvement in 48.8% of 
the patients. There was no influence of age, gender, 
body mass index, or BMC cell count on the result.
posItIon stateMents
The position statements here are based on the 
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survey of all the literature available, evidence synthesis 
based on randomized controlled trials, observational 
studies obtained from systematic reviews, guidelines, 
and finally an academic Delphi investigation performed 
on use of BMC to treat pain and musculoskeletal disor-
ders (3,49,50,78-112,491). 
STATEMENT 1
Based on a review of the literature in discussing 
the preparation of BMC using accepted methodologies, 
there is strong evidence of minimal manipulation in its 
preparation, and moderate evidence for homologous 
utility for various musculoskeletal and spinal conditions 
qualifies for the same surgical exemption.
STATEMENT 2
Assessment of clinical effectiveness based on exten-
sive literature shows emerging evidence for multiple 
musculoskeletal and spinal conditions.
• The evidence is highest for knee osteoarthritis with 
level II evidence based on relevant systematic reviews, 
randomized controlled trials, and nonrandomized 
studies. There is level III evidence for knee cartilage 
conditions. 
• Based on the relevant systematic reviews, random-
ized trials, and nonrandomized studies, the evi-
dence for disc injections is level III.
• Based on the available literature without appropri-
ate systematic reviews or randomized controlled 
trials, the evidence for all other conditions is level 
IV or limited for BMC injections.
STATEMENT 3
Based on an extensive review of the literature, there 
is strong evidence for the safety of BMC when performed 
by trained physicians with the appropriate precautions 
under image guidance utilizing a sterile technique.
STATEMENT 4
Musculoskeletal disorders and spinal disorders with 
related disability are common with extensive health 
care expenditures, taking a human toll with expendi-
tures in 2013 in the United States of $183 billion per 
year for musculoskeletal disorders, including back and 
neck pain. Even then, disability continues to escalate 
despite advancements with a wide array of treatment 
modalities.
STATEMENT 5
The 21st Century Cures Act was enacted in Decem-
ber 2016 with provisions to accelerate the development 
and translation of promising new therapies into clini-
cal evaluation and use. This bipartisan and bicameral 
legislation increased funding for medical research for 
combating the opioid epidemic and included measures 
to streamline approval of new therapies for clinical tri-
als. It also provided a new expedited biologics product 
development program called RMAT. Multiple activities 
have been enforced by regulatory agencies at the fed-
eral and state levels to combat overuse, misuse, fraud, 
and abuse; however, with no specific standards estab-
lished in delivery of BMC therapy.
STATEMENT 6
Development of cell-based therapies is rapidly prolifer-
ating in a number of disease areas, including musculoskele-
tal disorders and spine. With mixed results, these therapies 
are greatly outpacing the evidence (79,88,110,111,351-
373). The reckless publicity with unsubstantiated claims 
of beneficial outcomes having putative potential has led 
the FDA FTC to issue multiple warnings. Thus the US FDA is 
considering the appropriateness of using various therapies, 
including BMC, for homologous use.
STATEMENT 7
Since the 1980’s and the description of mesenchy-
mal stem cells by Caplan et al (120), (now called medici-
nal signaling cells [MSCs]), the use of  BMC in musculo-
skeletal and spinal disorders has been increasing in the 
management of pain and promoting tissue healing.
STATEMENT 8
As part of the regulation of HCT/Ps, including both 
autologous and allogenic bone marrow-derived tis-
sue preparations, are regulation by the FDA using the 
PHSA. If the biologic is minimally manipulated and falls 
under the same surgical procedure exemption found 
at 21 CFR 1271.15(b), the biologic is exempt from FDA 
regulation. BMC falls into this same surgical procedure 
exemption jurisdiction from a minimal manipulation 
standpoint, but only as long as it is also in treatments 
that constitute homologous use.
STATEMENT 9
If the FDA does not accept BMC as homologous, 
then it will require an IND classification with FDA (351) 
cellular drug approval for use. 
STATEMENT 10
This literature review and these position state-
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ments establish compliance with the FDA’s intent and 
corroborates its present description of BMC as homolo-
gous with same surgical exemption, and exempt from 
IND, for use of BMC for treatment of musculoskeletal 
tissues, such as cartilage, bones, ligaments, muscles, 
tendons, and spinal discs.
conclusIons
Based on the review of all available and relevant 
literature, position statements have been developed 
showing the impact of musculoskeletal and spine disor-
ders on health care costs, the opioid epidemic, and dis-
ability; evidence of minimal manipulation and homolo-
gous use based on MSCs and growth factors of BMC for 
multiple musculoskeletal structures including the disc; 
effectiveness and safety; and finally the evidence to 
show that BMC in musculoskeletal disorders meets the 
criteria of minimal manipulation and homologous use.
Consequently, using the FDA’s tiered, risk-based 
approach to the regulation of HCT/Ps, BMC is minimally 
manipulated within the same surgical procedure exemp-
tion, and meets criteria of homologous use. We hope 
that this review is helpful to regulators as they seek to 
regulate regenerative musculoskeletal medicine.  
Disclaimer
These position statements are based on the best 
available evidence and do not constitute inflexible 
treatment recommendations. Because of the chang-
ing body of evidence, this document is not intended 
to be a “standard of care.” These position statements 
are meant to provide a basis for the understanding be-
hind the role of BMC in the healing of musculoskeletal 
disorders, including the spine, to provide a source of 
appropriate indications for the use of BMC, to facilitate 
and to help standardize BMC. These statements are also 
to facilitate the FDA to continue to approve without 
IND classification for BMC in musculoskeletal and spi-
nal disorders. Finally, these statements are expected to 
encourage the performance of high-quality studies in 
an effort to document outcomes, and adverse conse-
quences, to advance BMC applications, and to encour-
age high-quality training and competency assessment, 
and the performance of high-quality studies in an ef-
fort to document outcomes, adverse consequences to 
advance BMC applications.
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